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Abstract
Unmeasured confounding is a common concern when clinical and health services researchers attempt to
estimate a treatment effect using observational data or randomized studies with non-perfect compliance. To
address this concern, instrumental variable (IV) methods, such as two-stage predictor substitution (2SPS)
and two-stage residual inclusion (2SRI), have been widely adopted. In many clinical studies of binary and
survival outcomes, 2SRI has been accepted as the method of choice over 2SPS but a compelling theoretical
rationale has not been postulated.
First, We directly compare the bias in the causal hazard ratio estimated by these two IV methods. Under the
potential outcome and principal stratification framework, we derive closed form solutions for asymptotic bias
in estimating the causal hazard ratio among compliers for both the 2SPS and 2SRI methods by assuming
survival time follows the Weibull distribution with random censoring. When there is no unmeasured
confounding and no always takers, our analytic results show that 2SRI is generally asymptotically unbiased
but 2SPS is not. However, when there is substantial unmeasured confounding, 2SPS performs better than
2SRI with respect to bias under certain scenarios. We use extensive simulation studies to confirm the analytic
results from our closed-form solutions. We apply these two methods to prostate cancer treatment data from
SEER-Medicare and compare these 2SRI and 2SPS estimates to results from two published randomized trials.
Next, we propose a novel two-stage structural modeling framework to understanding the bias in estimating
the conditional treatment effect for 2SPS and 2SRI when the outcome is binary, count or time to event. Under
this framework, we demonstrate that the bias in 2SPS and 2SRI estimators can be reframed to mirror the
problem of omitted variables in non-linear models. We demonstrate that only when the influence of the
unmeasured covariates on the treatment is proportional to their effect on the outcome that 2SRI estimates are
generally unbiased for logit and Cox models. We also propose a novel dissimilarity metric to quantify the
difference in these effects and demonstrate that with increasing dissimilarity, the bias of 2SRI increases in
magnitude. We investigate these methods using simulation studies and data from an observational study of
perinatal care for premature infants.
Last, we extend Heller and Venkatraman's covariate adjusted conditional log rank test by using the propensity
score method. We introduce the propensity score to balance the distribution of covariates among treatment
groups and reduce the dimensionality of covariates to fit the conditional log rank test. We perform the
simulation to assess the performance of this new method and covariates adjusted Cox model and score test.
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ABSTRACT
INSTRUMENTAL VARIABLE AND PROPENSITY SCORE METHODS FOR BIAS ADJUSTMENT
IN NON-LINEAR MODELS
Fei Wan
Nandita Mitra
Dylan Small
Unmeasured confounding is a common concern when clinical and health services researchers
attempt to estimate a treatment effect using observational data or randomized studies with non-
perfect compliance. To address this concern, instrumental variable (IV) methods, such as two-stage
predictor substitution (2SPS) and two-stage residual inclusion (2SRI), have been widely adopted.
In many clinical studies of binary and survival outcomes, 2SRI has been accepted as the method
of choice over 2SPS but a compelling theoretical rationale has not been postulated.
First, We directly compare the bias in the causal hazard ratio estimated by these two IV methods.
Under the potential outcome and principal stratification framework, we derive closed form solutions
for asymptotic bias in estimating the causal hazard ratio among compliers for both the 2SPS and
2SRI methods by assuming survival time follows the Weibull distribution with random censoring.
When there is no unmeasured confounding and no always takers, our analytic results show that
2SRI is generally asymptotically unbiased but 2SPS is not. However, when there is substantial
unmeasured confounding, 2SPS performs better than 2SRI with respect to bias under certain sce-
narios. We use extensive simulation studies to confirm the analytic results from our closed-form
solutions. We apply these two methods to prostate cancer treatment data from SEER-Medicare
and compare these 2SRI and 2SPS estimates to results from two published randomized trials.
Next, we propose a novel two-stage structural modeling framework to understanding the bias in
estimating the conditional treatment effect for 2SPS and 2SRI when the outcome is binary, count
or time to event. Under this framework, we demonstrate that the bias in 2SPS and 2SRI estimators
can be reframed to mirror the problem of omitted variables in non-linear models. We demonstrate
that only when the influence of the unmeasured covariates on the treatment is proportional to their
iv
effect on the outcome that 2SRI estimates are generally unbiased for logit and Cox models. We also
propose a novel dissimilarity metric to quantify the difference in these effects and demonstrate that
with increasing dissimilarity, the bias of 2SRI increases in magnitude. We investigate these meth-
ods using simulation studies and data from an observational study of perinatal care for premature
infants.
Last, we extend Heller and Venkatraman’s covariate adjusted conditional log rank test by using the
propensity score method. We introduce the propensity score to balance the distribution of covari-
ates among treatment groups and reduce the dimensionality of covariates to fit the conditional log
rank test. We perform the simulation to assess the performance of this new method and covariates
adjusted Cox model and score test.
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CHAPTER 1
INTRODUCTION
Evaluating the effectiveness of treatment and identifying the causal relationships between exposure
and disease are critical objectives for clinical and health services researchers. The casual effects
of a treatment can be rigorously defined under the potential outcomes framework (Holland, 1986;
Rubin, 2005). Consider a case of a two arm trial that involves one active treatment and a control
of no treatment. Let Zi denote binary treatment status variable, where Zi = 1 if subject i takes
the active treatment and Zi = 0 if subject i receives the control. Y Z=1i is the potential outcome,
on a continuous scale, when subject i receives the active treatment and Y Z=0i is the potential
outcome if subject i actually takes the control. The simple treatment effect for subject i is the
difference between the two potential outcomes, defined as Y Z=1i −Y Z=0i . Clearly, only one potential
outcome can be observed and the other one is often referred as “counter-factual” and written as
Yi = ZiY
Z=1
i + (1 − Zi)Y Z=0i . Therefore, it is not possible to identify the casual effect for an
individual because of this missing data issue (Rubin, 2005). However, the average casual effect
E(Y Z=1i − Y Z=0i ) for the population is identifiable from the data if certain assumptions are met.
Assume a binary treatment Z is randomized in the population and every subject complies with their
assignment. Under the exchange-ability and consistency assumptions (Hernán and Robins, 2006a;
Robins J.M. and Brumback, 2000), population average causal effect of treatment is consistently
estimated by the difference between two group means,
E(Y Z=1i − Y Z=0i ) = E(Yi|Zi = 1)− E(Yi|Zi = 0)
= Ȳ1 − Ȳ0
Although randomized controlled trials (RCT) are considered as the standard methodology to investi-
gate the causal effects of treatment because by design both observed and unobserved confounding
would be controlled, non-compliance frequently occurs when subjects fail to adhere to the treatment
assigned. Measured and unmeasured confounding factors may impact the outcome while causing
non-compliance of treatment (Cai, Small, and Ten Have, 2011). When the outcomes of patients
are compared by the actual treatment they receive, generally known as "as treated analysis", there
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may exist prognostic factors that influence patients’ compliance with treatment assignment. Thus,
the estimator of treatment effect is biased when confounding factors are not fully measured and
controlled for (Hernán and Hernández-Díaz, 2012). Alternatively, intention-to-treat analysis (ITT) is
a widely accepted simple approach to non-compliance and subjects are analysed according to ran-
domization scheme regardless of treatment actually received. Although the integrity of randomiza-
tion is retained, ITT tends to underestimate treatment effects, and it measures the causal effects of
treatment assignment, instead of effectiveness of treatment (Hernán and Hernández-Díaz, 2012).
Besides non-compliance problem, RCTs are subject to many other limitations, such as lack of gen-
eralizability, high cost, lengthy study period, ethic concerns, and difficulty in studying rare diseases,
etc (Nallamothu and Hayward, 2008). When a RCT is not feasible, non-randomized observational
studies are commonly used to examine the effectiveness of treatment or therapy in routine clini-
cal practice. Compared to RCTs, well designed observational studies can provide more realistic
results. Confounding, whether observed or not, is also the main problem of estimating the causal
effects in observational studies. The traditional statistical methods, such as stratification, matching,
multiple regression, and propensity score, have been used to reduce bias (Martens et al., 2006).
These methods are valid under the assumption of no unmeasured confounding variables. In many
cases, however, this assumption is very likely to be violated.
An alternative method that could potentially control for both measured and unmeasured confound-
ing variables is the instrumental variable (IV) method. An IV has the following properties: (i) IV
either correlates with or has causal effects on treatment or exposure; (ii) IV has no direct effects
on outcome except its indirect effects through either treatment or exposure. (iii) there is no un-
measured confounding for the association between IV and outcome variable (Angrist, Imbens, and
Rubin, 1996; Hernán and Robins, 2006b). Random assignment scheme in RCTs is an example of
IV.
IV method has been widely used in econometrics, as an alternative to ordinary least square method,
to obtain consistent parameter estimates in the presence of the endogenous regressors and it is
also commonly referred as structural equation model or two-stage least squares (Angrist, Imbens,
and Rubin, 1996; Martens et al., 2006). Because IV methods may consistently estimate the av-
erage causal effects of treatment even when unmeasured confounding is present (Newhouse and
McClellan, 1998), the interests in applying IV technique in outcomes research have been grow-
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ing. Terza, Basu, and Rathouz, 2008 made the extension of two IV based approaches, two-stage
residual inclusion (2SRI) and two-stage predictor substitution (2SPS), to correcting for endogeneity
bias in non-linear models for both binary and time to event outcome. When two IV methods are
compared for their performance in estimating the conditional odds ratio or hazard ratio (on unmea-
sured confounding), they conclude that only 2SRI method produces consistent estimates. This
finding rapidly increases the use of 2SRI method to control for unmeasured confounding in medical
research (Hadley et al., 2010; Tan et al., 2012).
Under the frame work of potential outcomes, Angrist, Imbens, and Rubin, 1996 divided the subjects
accordingly into four principal strata: 1) compliers, who always follow treatment assignment; 2)
always takers, who always take the treatment; 3) defiers, who always take the opposite to treatment
assignment; and 4) never takers, who never take treatment. They proved that IV estimator of
two-stage least squares method consistently estimates a local averaged treatment effects (LATE)
among compliers under five assumptions. The details of assumptions are discussed in Chapter
2. Under the same framework of potential outcomes and principal stratification, Cai, Small, and
Ten Have, 2011 found analytically and by simulation that both 2SRI and 2SPS logistic regressions
generated biased estimate of LATE among compliers. In chapter 2, under the same potential
outcome and principal stratification framework, we derive closed form solutions for asymptotic bias
in estimating the causal hazard ratio among compliers for both the 2SPS and 2SRI methods by
assuming survival time follows the Weibull distribution with random censoring.
In chapter 3, we further assess the performance of 2 stage IV methods in estimating the conditional
treatment effect given observed and unobserved covariates. For this purpose, we propose a novel
two-stage structural modeling framework to accommodate one endogenous treatment variable and
multiple unobserved covariates. This new framework is more relevant to clinical settings. Utilizing
this framework, we demonstrate that the bias in 2SPS and 2SRI estimators can be reframed to
mirror the problem of omitted variables in non-linear models. We demonstrate that only when
the influence of the unmeasured covariates on the treatment is proportional to their effect on the
outcome that 2SRI estimates are generally unbiased for logit and Cox models.
In contrast with instrumental variable method, Propensity score method is a common approach
to control for confounding bias under no unmeasured confounder assumption. In chapter 4, we
explore another use of propensity score method in estimating the conditional hazard ratio given
3
observed covariates. Covariates adjusted cox proportional hazard model is frequently used when
proportional hazard assumption holds. Heller and Venkatraman, 2004 proposed a nonparametric
covariate adjusted conditional log rank test to compare survival distributions among different treat-
ment groups. This method is robust when proportional hazard assumption is violated and also
does not require any independence assumption between treatment variable and covariates. How-
ever, their approach is valid for no more than three covariates. We use the propensity score to
balance the distribution of covariates among treatment groups and reduce the dimensionality of co-
variates to circumvent the limitations of the conditional log rank test. We performed the simulation
to assess the performance of this new method and covariates adjusted Cox model and score test.
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CHAPTER 2
BIAS IN TWO STAGE INSTRUMENTAL VARIABLE METHODS
2.1. Introduction
Evaluating the effectiveness of treatment and identifying the causal relationship between exposure
and disease are critical objectives for clinical and health services researchers. Confounding is often
a concern when analyzing non-randomized observational studies and even randomized studies with
non-compliance (Hernán and Robins, 2006b). Instrumental variable (IV) methods are increasingly
being used in clinical comparative effectiveness studies to potentially control for both measured
and unmeasured confounding. Angrist, Imbens, and Rubin, 1996 defined the IV for causal effects
of treatment on outcome to be a variable satisfying the following five assumptions: i)The potential
outcomes on one subject are unrelated with the particular assignment of treatment to the other
subjects; ii) IV is randomly (or ignorably) assigned; iii) Any effect of IV on the outcome must be
mediated by treatment received(the exclusion restriction);iv) IV has nonzero effect on treatment
received; v) There are no defiers. (for details see section 2.2)
In a recent clinical study, we were interested in comparing the effectiveness of two treatments for
prostate cancer in elderly men using SEER-Medicare, a large national observational database.
Specifically, we planned to use IV methods to estimate the effect of the addition of external beam
radiation therapy (EBRT) to androgen suppression therapy (ADT) in improving overall survival in
men with locally advanced prostate cancer. We considered a commonly used IV in health services
research: local area treatment patterns defined by the percentage of active treatment in hospital
referral regions (HRR). This IV has been shown to capture regionally distinct structural variation
in care (Bekelman et al., 2015). Such variation is not fully explained by patient characteristics.
Further, this IV varies across HRRs and is strongly associated with treatment assignment. Finally, it
is balanced across important observed prognostic factors. Although there is an extensive literature
on the importance of choosing an appropriate instrument, less attention has been paid to using the
appropriate modeling approach once an IV is selected.
Recently, there has been rapid uptake and widespread use of two IV based analytic approaches
called two-stage residual inclusion (2SRI) and two-stage predictor substitution (2SPS)(Cai, Small,
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and Ten Have, 2011; Terza, Basu, and Rathouz, 2008).These methods have been used to cor-
rect for bias due to endogeneity in non-linear models for both binary and time-to-event outcomes.
Among these two IV approaches, 2SRI was shown to consistently estimate a conditional causal
parameter under certain assumptions (Terza, Basu, and Rathouz, 2008) and has been adopted
as the method of choice in clinical research studies involving survival outcomes(Gore et al., 2010;
Hadley et al., 2010; Tan et al., 2012). The conditional causal parameter that Terza, Basu, and
Rathouz, 2008 consider is only identified by making homogeneity assumptions that go beyond the
five assumptions for a valid IV defined in the first paragraph. Angrist, Imbens, and Rubin, 1996
showed that under these five assumptions for a valid IV, the only treatment effect that is identified is
the average treatment effect for the compliers, where the the compliers are the subjects who would
take the treatment if encouraged to do so by the IV but would not take the treatment if not encour-
aged by the IV; this is called the local average treatment effect (LATE).In the context of a binary
outcome, Cai, Small, and Ten Have, 2011 demonstrated that both the 2SRI and 2SPS methods
generated biased estimates of LATE among compliers for binary outcome. In this paper, we focus
on the properties of 2SPS and 2SRI as estimators of the LATE for time-to-event data.
Despite the fact that there is growing interest in applying two stage IV methods to time-to-event data,
little is known about the potential bias of using such methods to estimate LATE among compliers.
We derive closed form expressions of the bias and conduct extensive simulations to quantify this
bias. We then apply both of the two-stage IV methods to our prostate cancer treatment data and
compare them to the results from two published randomized clinical trials (Warde et al., 2011;
Widmark et al., 2009)
2.2. Notation, Assumptions, Compliance Categories, and Model
2.2.1. Notation
Following the notation of Cai, Small, and Ten Have, 2011 and Nie, Cheng, and Small, 2011, an
N-dimensional vector of binary IV is represented by R. An IV value of 1 represents encouragement
to receive the active treatment and 0 represents no encouragement to receive the active treatment.
In a RCT setting, where the IV is the randomized assignment, then an IV value of 1 represents
random assignment to treatment and 0 represents random assignment to control; in the prostate
cancer observational study described in the introduction, an IV value of 1 represents a high local
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area rate (above median) of adding EBRT to ADT and 0 represents a low local area rate (below the
median) of adding EBRT to ADT. The ith element Ri = 1 implies that subject i is encouraged to
receive the active treatment, whereas Ri = 0 indicates that subject i is not encouraged to receive
the active treatment. Let ZR be an N-dimensional vector of potential treatment received given R,
and ith element ZRi =1 indicates that subject i receives the active treatment and Z
R
i =0 means that
subject i receives the control under R.
Similarly, we define TR,Z to be an N-dimensional vector of potential survival time under R and Z,
and ith element TR,Zi is the potential survival time for subject i under R and Z. Let L
R,Z to be
an N-dimensional vector of potential censoring time under R and Z, and ith element LR,Zi is the
potential censoring time for subject i under R and Z.
We define Y R,Z=min{TR,Z , LR,Z}, the elementwise minimum of potential censoring and survival
times,to be an N-dimensional vector of potential observed follow up time under R and Z, and ith
element Y R,Zi represents the potential follow up time for subject i under R and Z. Let δ
R,Z
i =
I{TR,Zi ≤ C
R,Z
i } indicates whether subject i is observed to terminate by failure (δ
R,Z
i = 1) or by
censoring (δR,Zi =0) given R and Z. The vector Xi represents measured confounding variables for
subject i.
2.2.2. Assumptions
The main assumptions we will make for causal modeling are the five assumptions made by Angrist
et al. (Angrist, Imbens, and Rubin, 1996), and a random censoring assumption for the survival
setting.
1) Stable Unit Treatment Value Assumption (SUTVA)(Rubin, 1986, 1990)
a. if Ri=R′i, then Z
R
i = Z
R′
i
b. if Ri = R′i and Zi = Z
′
i, then Y
R,Z
i = Y
R′,Z′
i
The SUTVA assumption says that the potential outcomes for subject i are not related with the treat-
ment status of other subjects such that we can write ZRi ,Y
R,Z
i , T
R,Z
i , L
R,Z
i ,δ
R,Z
i as Z
Ri
i ,Y
Ri,Zi
i ,T
Ri,Zi
i ,L
Ri,Zi
i ,
δRi,Zii respectively. The SUTVA assumption also implies the assumption of consistency, such that
the value of the potential outcome given a treatment remains unchanged no matter what the treat-
ment assignment mechanism is (Rubin, 1986)
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2) Independence of the instrument R (Abadie, 2003):
Conditional on a vector of confounders X, the random vector (Y R,Z , TR,Z , LR,Z , ZR) is indepen-
dent of R. In a randomized trial where R is the IV, the independence assumption holds without
conditioning on X.
3) Exclusion Restriction
∀Z,R, and R′, we have:
TR,Z = TR
′,Z , LR,Z = LR
′,Z , Y R,Z = Y R
′,Z , This assumption implies that any effect of IV on
potential outcomes must be through its effect on treatment actually received. Thus, we can write
T
R,Z
i , L
R,Z
i ,Y
R,Z
i as T
Zi
i , L
Zi
i ,Y
Zi
i by combining the exclusion restriction and SUTVA assumptions.
4) Non-zero Average Causal Effect of R on Z
E[Z1i − Z0i ] 6= 0
This assumption means the IV is correlated with treatment received.
5) Monotonicity (Imbens and Angrist, 1994)
Z1i ≥ Z0i ,∀i ∈ N
This assumption rules out the existence of defiers. No subject always does the opposite of the
treatment assigned.
6) Independent censoring
The distribution of potential survival time TR,Z is independent of the distribution of potential cen-
soring time LR,Z .
2.2.3. Compliance Categories
Under the framework of principal stratification and potential outcomes (Angrist, Imbens, and Rubin,
1996; Rubin, 2005), subjects in a two-arm randomized trial can be categorized into 4 principal
strata: Always takers (AT) are subjects who always take the treatment regardless of assignments
(Z1 = 1, Z0 = 1); Compliers (C) are subjects who comply with their assignments(Z1 = 1, Z0 = 0);
Never takers (NT) are the subjects who never take the treatment no matter which group they are
assigned to(Z1 = 0, Z0 = 0); Defiers (D) are the subjects who take the treatment opposite of their
assignments(Z1 = 0, Z0 = 1).
8
2.2.4. Model
We first define the probability of receiving the treatment Pr(R = 1) = r, the probability of being a
always taker Pr(AT ) = ρa, and the probability of being a complier Pr(C) = ρc. We also define
the probability of being a defier Pr(D) = ρd, but under the monotonicity assumption, there are no
defiers so that ρd = 0. Hence, the probability of being a never taker Pr(NT ) is equal to 1− ρa− ρc.
We assume both potential censoring time and potential survival time follow the Weibull distribution
with the same shape parameter α. The potential censoring time for the subjects in each principal
strata follows Weibull(α, λ), and we define the parameters of the probability distribution of potential
survival time for each principal strata as follows:
T 1|AT ∼Weibull(α, θ1at), T 0|AT ∼Weibull(α, θ0at)
T 1|C ∼Weibull(α, θ1c ), T 0|C ∼Weibull(α, θ0c )
T 1|NT ∼Weibull(α, θ1nt), T 0|NT ∼Weibull(α, θ0nt)
We also examined scenarios in which different shape parameters α’s are assumed for the po-
tential censoring time and the potential survival time. These details are given in Appendix E.
The density of Weibull distribution is f(t) = (α/K)(t/K)K−1exp(−(t/K)α) and the hazard rate
is h(t) = αK−αtα−1. In the case of Weibull regression with covariates X, K−α can be reparame-
terized as exp(βX). The hazard rate for the compliers if treated is h(T 1 = t|C) = αtα−1(θ1c )−α. The
hazard rate for the compliers if not treated is h(T 0 = t|C) = αtα−1(θ0c )−α. Hence, the log causal
hazard ratio φ for the compliers is the difference between two log hazard rates:
φ = log[h(T 1 = t|C)]− log[h(T 0 = t|C)]
= −α(log(θ1c )− log(θ0c ))
2.3. Two Stage Predictor Substitution(2SPS)Method
The 2SPS method is frequently used and simple to implement (Terza, Basu, and Rathouz, 2008).
In the first stage, the treatment received Z is regressed on the IV-treatment assignment R, and let
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P = E(Z|R). In the second stage, a log linear model including P ,defined as:
log[h(Y |P )] = η + ξP + log(h0(y)), h0(Y ) = αyα−1
is fitted to estimate the coefficient ξ. This is 2SPS estimator of the log causal hazard ratio. We first
derive a closed form expression to the probability limit of the maximal likelihood estimator (M.L.E)
of ξ, then take the difference between this probability limit and true log causal parameter φ for the
expression of the asymptotic bias of the 2SPS estimator as an estimator of the log causal hazard
ratio for compliers.
2.3.1. Probability limit of M.L.E of causal parameter
Let P̂ denote the predicted value from the estimated binary regression model. i.e., P̂ = Ê(Z|R).
When P̂ is substituted for P , the second stage Weibull model becomes:
log[λ(Y |P̂ )] = η∗ + ξ∗P̂ + log(h∗0(y))
Let ξ̂∗ and ξ̂ denote the estimators (M.L.E) of ξ∗ and ξ respectively. As sample size n→∞, P̂ → P ,
ξ̂∗
p−→ ξ̂, and ξ̂ p−→ ξ. Therefore, ξ̂∗ p−→ ξ. To derive closed form expression for the asymptotic bias, we
need to re-express ξ in terms of parameters specified in Section 2.2 under the principal stratification
framework.
Only always takers receive the treatment when assigned to control(R = 0). Both always takers and
compliers take the treatment when assigned to treatment(R = 1). Thus, it can be shown that (Cai,
Small, and Ten Have, 2011):
p0 = E(Z|R = 0) = ρa, p1 = E(Z|R = 1) = ρa + ρc
Since P = {p0, p1} is an one-to-one transformation of R = {0, 1}, we have the following for the
second stage Weibull regression:
log(h(Y |R = 0)) = log(h(Y |P = p0))
= η + ξp0 + log(h0(y)) (2.1)
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and,
log(h(Y |R = 1)) = log(h(Y |P = p1))
= η + ξp1 + log(h0(y)) (2.2)
Instead of working with a second stage model involving P , we can work with a model involving R
instead. Solving (2.1) and (2.2), we have:
ξ =
log(h(Y |R = 1))− log(h(Y |R = 0))
p1 − p0
(2.3)
The log linear model including R assumes two underlying Weibull distributions of the same shape
parameter α∗, Weibull(α∗,K0) and Weibull(α∗,K1), for subjects assigned to control (R = 0) and
treatment (R = 1) respectively. Thus, (2.3) can be expressed as:
ξ =
log(K−α
∗
1 )− log(K−α
∗
0 )
ρc
, K−α
∗
1 = e
η+ξp1 , K−α
∗
0 = e
η+ξp0 (2.4)
It is worth noting that both follow up times of subjects assigned to control, denoted as Y |R = 0,
and follow up times of subjects assigned to treatment, denoted as Y |R = 1, actually follow mixture
distributions consisting of three different Weibull distributions. Details are given in Appendix A.
However, the second stage Weibull model of 2SPS method imposes the two Weibull distributions,
with the same shape parameter α∗ but different scale parameters K0,K1, upon subjects assigned
to treatment(R = 1) or assigned to control(R = 0) respectively. Thus, the M.L.E of α∗,K0,K1
are derived by maximizing the likelihood function Ln(α∗,K0,K1) that consists of products of two
Weibull densities: Weibull(α∗,K0) and Weibull(α∗,K1).
Let α̂∗ denote the M.L.E of α∗ and We set E(∂log(Ln(α
∗,K̂0(α
∗),K̂1(α
∗))
∂α∗ ), the expectation of score
equation derived from profile likelihood of α∗, equal to 0 and let α̃∗ be the solution. Under the
assumptions stated in Section 2.2 and consistency of M.L.E, the probability limit of the estimator
α̂∗ is α̃∗. Details are given in Appendix C. Once the parameters of the principal strata are defined,
α̃∗ can be solved numerically using a root-finding algorithm such as the "bisection" method. Let
K̂0, K̂1 be the M.L.Es of the two scale parameters K0,K1 respectively. After the value of α̃∗ is
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determined, the probability limits of the estimators K̂0, K̂1 can be derived as follows:
K̃0 = [
1
P (δ = 1|R = 0)×
{ρaΓ(
α̃∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α̃
∗/α + ρnΓ(
α̃∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α̃
∗/α + ρcΓ(
α̃∗
α
+ 1)[
1
θ0c
α +
1
λα
]−α̃
∗/α}]1/α̃∗
(2.5)
and,
K̃1 = [
1
P (δ = 1|R = 1)×
{ρaΓ(
α̃∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α̃
∗/α + ρnΓ(
α̃∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α̃
∗/α + ρcΓ(
α̃∗
α
+ 1)[
1
θ1c
α +
1
λα
]−α̃
∗/α}]1/α̃∗
(2.6)
The detailed steps of the derivation of (2.5) and (2.6) are given in Appendix C. By substituting (2.5) and (2.6)
into (2.4), we derive the expression of log causal hazard ratio ξ as the following:
ξ = {log([ 1
P (δ = 1|R = 1)×
{ρaΓ(
α̃∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α̃
∗/α + ρnΓ(
α̃∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α̃
∗/α + ρcΓ(
α̃∗
α
+ 1)[
1
θ1c
α +
1
λα
]−α̃
∗/α}])−1
− log([ 1
P (δ = 1|R = 0)×
{ρaΓ(
α̃∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α̃
∗/α + ρnΓ(
α̃∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α̃
∗/α + ρcΓ(
α̃∗
α
+ 1)[
1
θ0c
α +
1
λα
]−α̃
∗/α}])−1}
× 1
ρc
(2.7)
Thus, (2.7) is the closed-form expression of the probability limit of the log causal hazard ratio estimator ξ̂∗ from
the 2SPS Weibull model.
2.3.2. Bias analysis
The asymptotic bias of the causal parameter ξ of the 2SPS Weibull regression model is simply the difference
between the true log causal hazard ratio φ and the derived closed form expression of ξ, such that
B2sps = ξ + α(log(θ
1
c)− log(θ0c)) (2.8)
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We can re-paramterize θ0nt in (2.8) with one additional parameter ∆ = −α(log(θ0nt)− log(θ0c)) as the following:
log(θ0nt) = log(θ
0
c) +
∆
α
(2.9)
∆ in (2.9) is the log hazard ratio between never takers and compliers given no treatment. It can be interpreted
as the magnitude of the unmeasured confounding because the differences between principal strata are at-
tributable to the unmeasured confounding (Cai, Small, and Ten Have, 2011). When ∆ = 0 or θ0nt = θ0c ,there is
no unmeasured confounding.
We make the following observations about the bias of 2SPS method from (3.11): 1) When α = 1 and we
treat α∗ as a known parameter and fix it at 1, that is the scenario when the survival outcomes of all principal
strata follow exponential distributions and we also fit an exponential model in the second stage instead of
estimating the shape parameter for a more general form of Weibull distribution; 2) When ρc = 1, every subject
is a complier and (2.8) can be simplified as 1
α∗ −
γ
α
− ψ(α
∗
α
+ 1) 1
α
= 0. Then we have α̃∗ = α. Setting
ρc = 1,ρa = 0, and ρn = 0, (2.8) becomes 0 so that bias B2sps = 0 when a randomized controlled trial has
perfect compliance; 3) When there is no causal effect (θ1c = θ0c ), all terms in (2.8) cancel out and we have
B2sps = 0; 4) When ρa = 0 and θ0c = θ0n, there is no confounding because there are no always takers and
never takers can’t get treatment so that the confounding can only be attributable to the difference between
never takers and compliers given no treatment(Cai, Small, and Ten Have, 2011). However, (2.8) can not be
reduced to 0 under this setting so that the bias of 2SPS method B2sps is generally not 0 even when there is no
confounding. 5) λ, the scale parameter of the censoring distribution is involved in bias equation (2.9), which
coincides with the results in Struthers and Kalbfleisch(Struthers and Kalbfleisch, 1986).
We can analyze how parameters influence the relationship between the magnitude of confounding and bias
using derived closed form expression (2.9). For the purpose of demonstration only, here we create four
scenarios in which there are no always takers. The results are revealed in Figure 2.1 (a)-(d).
In Figure 2.1, we can clearly see that the bias of the 2SPS method is not 0 when there is no confounding. The
bias increases with the larger shape parameter α of the survival function (within each principal stratum).The
bias is the smallest when we have an decreasing hazard rate (α < 1) and the highest when we have an
increasing hazard rate(α > 1). By comparing Figure 2.1 (a) and (b), we also observe that the bias decreases
as the compliance rate increases from 0.5 to 0.8. When the scale parameter (θc) is smaller, the bias is also
smaller (Figure 2.1 (a) vs. (c)). Although the probability of being randomly assigned to the treatment group is
involved in computing the shape parameter of the second stage Weibull regression model, its effects on the
bias are very small (compare Figure 2.1 (b) to (d)).
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2.4. Two Stage Residual Inclusion(2SRI)Method
Similar to the 2SPS method, the 2SRI method involves two stage modeling (Terza, Basu, and Rathouz, 2008).
In the first stage, we regress the treatment received Z on the IV-treatment assignment R and calculate the
residual term E = Z − E(Z|R). In the second stage, we fit a log linear model on both treatment received
variable Z and residual E as,
log(h(Y |Z,E))) = λ0 + λ1Z + λ2E + log(h0(y)), h0(Y ) = αyα−1 (2.10)
, to estimate the regression coefficient λ1. This is 2SRI estimaor of the log causal hazard ratio. We derive the
probability limit of the M.L.E of λ1 first and then calculate the asymptotic bias by taking the difference between
this probability limit of the estimator and true log causal hazard ratio among compliers.
2.4.1. Probability limit of M.L.E of causal parameter
As discussed in a previous study (Cai, Small, and Ten Have, 2011), (2.10) is not the true model for the hazard
function h(Y |Z,E). In fact the true model includes the interaction term between Z and E. However, deriving
the closed-form expression for the probability limit of the estimator from (2.10) is very difficult when (2.10) is
not the true model. With one additional assumption that there are no always takers, (2.10) becomes the true
model. We derive a closed-form expression of the probability limit of the estimator of causal parameter λ1
assuming that there are no always takers and thus (2.10) is the true model. Let Ê denote the residuals from
the estimated binary regression model in the first stage. i.e., Ê = Z − Ê(Z|R). When Ê is substituted for E,
(2.10) becomes:
log[h(Y |Z, Ê)] = λ∗0 + λ∗1Z + λ∗2Ê + log(h∗0(y))
Let λ̂∗1 and λ̂1 be the estimators (M.L.E) of λ∗1 and λ1. As sample size n→∞, Ê → E , λ̂∗1
p−→ λ̂1, and λ̂1
p−→ λ̂1.
Thus, λ̂∗1
p−→ λ1. To derive a closed form expression for the asymptotic bias, we need to first re-express λ1 in
terms of the parameters specified in section 2.3 under the principal stratification framework.
As shown in a previous study (Cai, Small, and Ten Have, 2011), under the no always taker assumption, the
first stage binary regression is E(Z|R) = ρa + ρcR and residual term E = Z −E(Z|R), thus the residual term
can be re-expressed as E = Z − ρa − ρcR. Since {Z,E} has an one to one relationship with {Z,R}, we can
establish the following equivalence between the model involving {Z,E} and the model involving {Z,R}for the
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second stage Weibull model:
log(h(Y |Z,E)) = λ0 + λ1Z + λ2E + log(h0(y))
= λ0 + λ1Z + λ2(Z − ρa − ρcR) + log(h0(y))
= log(h(Y |Z,R)) (2.11)
Under the no always taker assumption, the second stage Weibull regression model defined by (2.10) assumes
the three underlying Weibull distributions with the same shape parameter but different scale parameters for
subjects in the three different subgroups: 1) ∼ Weibull(α∗,K0) for those who are assigned to treatment and
receive the treatment actually (Z = 1, R = 1). Only compliers are in this group; 2)∼Weibull(α∗,K1) for those
who are assigned to treatment but do not receive the treatment actually (Z = 0, R = 1), This group has only
never takers; 3) ∼ Weibull(α∗,K2) for those who are assigned to control and do not receive the treatment
(Z = 0, R = 0), both never takers and compliers are in this group. There are no subjects that are assigned to
control but still take the active treatment (Z = 1, R = 0) under the assumption of no always takers. Thus, the
M.L.E of α∗,K0,K1,K2 are derived by maximizing the likelihood function Ln(α∗,K0,K1,K2) that consists of
products of three Weibull densities: Weibull(α∗,K0), Weibull(α∗,K1),and Weibull(α∗,K2).
Let α̂∗ denote the M.L.E of α∗ and set E( ∂log(Ln(α
∗,K̂0(α
∗),K̂1(α
∗),K̂2(α
∗))
∂α∗ ),the expectation of score equation
derived from profile likelihood of α∗, to 0 and let α̃∗ be the solution. Under the assumptions stated in section
2.2 and consistency of the M.L.E, the probability limit of the estimator α̂∗ is α̃∗. Details are given in Appendix
D. With the parameters of principal strata defined, α̃∗ can be solved numerically using a root-finding algorithm.
Let K̂0, K̂1, K̂2 be the M.L.Es of two scale parameters K0,K1,K2. Once the value of α̃∗ is determined, we
compute the probability limits of the estimators K̂0, K̂1, K̂2 as follows:
K̃0 = [
Γ( α̃
∗
α
+ 1)[ 1
θ1c
α + 1λα ]
−α̃∗/α
1
1+(
θ1c
λ
)α
]1/α̃
∗
(2.12)
and
K̃1 = [
Γ( α̃
∗
α
+ 1)[ 1
θ0nt
α + 1λα ]
−α̃∗/α
1
1+(
θ0nt
λ
)α
]1/α̃
∗
(2.13)
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and
K̃2 = [
Γ( α̃
∗
α
+ 1)[ 1
θ0nt
α + 1λα ]
−α̃∗/αρnt + Γ(
α̃∗
α
+ 1)[ 1
θ0c
α + 1λα ]
−α̃∗/αρc
1
1+(
θ0nt
λ
)α
ρnt +
1
1+(
θ0c
λ
)α
ρc
]1/α̃
∗
(2.14)
The derivation of (2.12),(2.13) and (2.14) is detailed in Appendix D. Based on (2.11), we can establish the
following three equations with all possible combination of values of Z and R excluding the always takers
scenario(Z=1,R=0).
1) When Z=1 and R=1, there are only compliers in this subgroup.
log(h(Y |Z = 1, R = 1)) = log(h(Y (1)|Z = 1, R = 1))
→ λ0 + λ1 + λ2(1− ρC) = log(K̃0
−α̃∗
)
= log([
Γ( α̃
∗
α
+ 1)[ 1
θ1c
α + 1λα ]
−α̃∗/α
1
1+(
θ1c
λ
)α
]−1) (2.15)
2) When Z=0 and R=1, there are only never takers in this subgroup.
log(h(Y |Z = 0, R = 1)) = log(h(Y (0)|Z = 0, R = 1))
→ λ0 + λ2(−ρC) = log(K̃1
−α̃∗
)
= log([
Γ( α̃
∗
α
+ 1)[ 1
θ0nt
α + 1λα ]
−α̃∗/α
1
1+(
θ0nt
λ
)α
]−1) (2.16)
3) When Z=0 and R=0, there are mixture of both never takers and compliers in this subgroup.
log(h(Y |Z = 0, R = 0)) = log(h(Y (0)|Z = 0, R = 0))
→ λ0 = log(K̃2
−α̃∗
)
= log([
Γ( α̃
∗
α
+ 1)[ 1
θ0nt
α + 1λα ]
−α̃∗/αρnt + Γ(
α̃∗
α
+ 1)[ 1
θ0c
α + 1λα ]
−α̃∗/αρc
1
1+(
θ0nt
λ
)α
ρnt +
1
1+(
θ0c
λ
)α
ρc
]−1) (2.17)
We then derive the closed form expression for the causal parameter λ1 by solving (2.15),(2.16),and (2.17) for
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λ1 as follows:
λ1 = log([
Γ( α̃
∗
α
+ 1)[ 1
θ1c
α + 1λα ]
−α̃∗/α
1
1+(
θ1c
λ
)α
]−1)
− log([
Γ( α̃
∗
α
+ 1)[ 1
θ0nt
α + 1λα ]
−α̃∗/αρnt + Γ(
α̃∗
α
+ 1)[ 1
θ0c
α + 1λα ]
−α̃∗/αρc
1
1+(
θ0nt
λ
)α
ρnt +
1
1+(
θ0c
λ
)α
ρc
]−1)
− 1− ρC
ρC
(log([
Γ( α̃
∗
α
+ 1)[ 1
θ0nt
α + 1λα ]
−α̃∗/αρnt + Γ(
α̃∗
α
+ 1)[ 1
θ0c
α + 1λα ]
−α̃∗/αρc
1
1+(
θ0nt
λ
)α
ρnt +
1
1+(
θ0c
λ
)α
ρc
]−1))
− log([
Γ( α̃
∗
α
+ 1)[ 1
θ0nt
α + 1λα ]
−α̃∗/α
1
1+(
θ0nt
λ
)α
]−1)
2.4.2. Bias analysis
To compute asymptotic bias of the 2SRI method, we subtract the true log hazard ratio φ from the
closed-form expression of λ1.
B2SRI = λ1 + α(log(θ
1
c )− log(θ0c )) (2.18)
We can re-parameterize θ0nt in (2.18) in the way as in Section 2.3 and let θ0nt = θ0ce
∆
α . From the
derived expression of asymptotic bias of 2SRI estimator, we can make the following observations:
1) When α = 1, the survival outcome within a principal stratum follows an exponential distribution. If
we treat α∗ as known and set α∗ = 1, it means we fit an exponential regression model in the second
stage; 2)When there is perfect compliance (ρc = 1), we have B2SRI = 0. In this scenario, α̃∗ = α.
By plugging ρc = 1 into (2.18), we can easily verify the results; 3) When there is no confounding
(θ0c = θ0n), B2SRI = 0; 4) When there is no causal effect (θ1c = θ0c ), B2SRI is not 0; 5) λ, the scale
parameter of the censoring distribution is involved in bias equation (2.18), similar to the findings for
2SPS method.
We can analyze how parameters influence the relationship between the magnitude of confounding
and bias from the 2SRI method using (2.18). Similar to the previous section, four scenarios were
created assuming there are no always takers. The results are shown in Figure 2.2 (a)-(d). In Figure
2.2, it is apparent that the bias of the 2SRI method is 0 when there is no confounding. Intuitively,
under the condition of no confounding, substituting the term of the estimated residuals in the second
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stage survival model has no effect on the estimate of the causal parameter. By comparing Figure
2.2 (a) and (b), we also observe that the bias decreases as the compliance rate increases from 0.5
to 0.8. When the scale parameter (θc) is smaller, the bias tends to be smaller (Figure 2.2 (a) vs.
(c)). The probability of being randomly assigned to the treatment group has very small impact on
the bias(compare Figure 2.2 (b) to (d)).
2.5. Simulation
2.5.1. Simulation algorithm
We follow the five step algorithm used by Cai, Small, and Ten Have, 2011 to generate data for a
simulation study. In the first step, a data set of N subjects is generated. Always takers, compliers,
and never takers among these subjects are generated from a multinomial distribution with probabil-
ities {ρa, ρc, ρn}. At the second step, treatment assignment status R is generated for each subject
with probability P (R = 1) = ρr. Because outcome in the present study is time to event, we modified
step 3 to generate potential survival time {T 0, T 1}and censoring time {L0, L1} for each principal
stratum based on the parameters θ0at, θ0c , θ0nt, θ1at, θ1c , θ1nt, λ. For instance, if a subject is a complier,
the potential time to death under control T 0c is generated from weibull(α, θ0c ) and the potential time
to death under treatment T 1c is generated from weibull(α, θ1c ). The potential censoring time {L0c , L1c}
are generated from weibull(α, λ). At step 4, we use compliance status (always taker, complier, or
never taker) and treatment assignment status R to determine the treatment received status Z. For
instance, if a subject is a complier and assigned to treatment group (R = 1), then Z = 1. If a subject
is an always taker but assigned to the control group, then Z = 0. At step 5, the observed survival
time and censoring time are generated as follows:
T = T 1Z + T 0(1− Z), and L = L1Z + L0(1− Z)
and finally observed follow up time and censoring indicator are given as:
Y = min(T, L), and δ = I(L ≥ T )
2.5.2. Simulation results
To demonstrate the consistency between the derived closed form expressions and the asymptotic
biases from the 2SPS and 2SRI approaches under the assumption of no always takers(ρa = 0),
we ran the simulation 2000 times, with the sample size n=10000, according to the same parameter
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settings presented in Figure 2.1 d) and Figure 2.2 d). Table 2.1 shows simulation results from 4
scenarios (α = 0.5, 1, 1.5, 2). As shown in this table, the biases from simulated results are consistent
with the values computed with the derived analytic formula for both the 2SPS and 2SRI Weibull
models.We also considered 2SPS and 2SRI Cox models (the second stage regression is a Cox
model instead of a Weibull model). The pattern of the biases from 2SPS and 2SRI Cox models
remains the same as for the 2SPS and 2SRI Weibull models respectively. With decreasing hazard
(α = 0.5), the bias from using the 2SPS approach is smaller than the bias from the 2SRI approach.
When the hazard is constant or increasing (α ≥ 1), the results are mixed. With stronger negative
confounding, the 2SPS method produces smaller bias than the 2SRI method. However, with no
confounding or stronger positive confounding, the 2SPS method produces larger bias than the
2SRI method.
To evaluate the performance of both 2SPS and 2SRI methods in the setting where there are al-
ways takers, we simulated the data with various combination of parameters based on the following
settings: i) Shape parameter α varies among {0.5, 1, 2}, which represent decreasing, constant, and
increasing hazard scenarios; ii)Probabilities of being always takers ρa and compliers ρc were set to
3 combinations: {0.2, 0.7},{0.7, 0.2}, and {0, 0.5}. In this way, low, medium, and high levels of com-
pliance were represented; iii) probability of being assigned to treatment ρr were set to {0.1, 0.5} to
reflect both new and relatively established treatments; iv) Scale parameter of censoring distribution
were set to {0.5, 1, 2}; v) Each of the parameters θ0at, θ0c , θ1c was set to {0.5, 1, 3} separately. Thus,
1458 possible combinations were created. For each setting, we generated 10,000 observations
and fit the 2SPS and 2SRI models to the data. This process was repeated 2000 times.
The results are presented in Figure 2.3. The magnitude of bias increases with increasing magni-
tudes of unmeasured confounding. As the value of shape parameter α increases, the magnitude
of bias increases. In the scenarios with decreasing hazard, the 2SPS method outperforms the
2SRI method. The 2SRI method tends to have larger asymptotic bias when the magnitude of un-
measured confounding is large. In the scenarios with constant hazard, the 2SPS method slightly
outperforms the 2SRI method when the magnitude of unmeasured confounding is large. In the sce-
narios with increasing hazard, both approaches produce larger biases. The 2SRI method performs
better when the magnitude of unmeasured confounding is small. When there are always takers, the
2SRI method could be biased even when there is no measured confounding. We also compared
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the two methods using mean square error and the conclusions remain the same (2.4).
2.6. Seer-Medicare Prostate Cancer Study
Prostate cancer is the highest prevalence non-skin malignancy among American men (In 2011,
there were an estimated 2,707,821 men living with prostate cancer in the United States. The
number of deaths was 23.0 per 100,000 men per year). Unlike prostate cancers that are diagnosed
at an early stage, locally advanced prostate cancer is associated with substantial morbidity and
mortality. Radiation therapy is a common treatment for locally advanced prostate cancer. Two
randomized trials recently demonstrated that radiation therapy reduces mortality for men with locally
advanced tumors who also receive systemic androgen deprivation (Warde et al., 2011; Widmark
et al., 2009). However, both trials excluded elderly patients and those with early stage, PSA-
screen detected cancer and therefore had less generalizability, a common criticism of randomized
evidence. Therefore, we applied two-stage IV methods to evaluate survival outcomes in locally
advanced prostate cancer, assessing survival outcomes of androgen deprivation therapy with or
without radiation therapy in comparison to the randomized trials.
We analyzed data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database.
The SEER-Medicare database links patient demographic and tumor-specific data collected by
SEER cancer registries to Medicare claims for inpatient and outpatient care. We considered pa-
tients with prostate cancer diagnosed between January 1, 1995 and December 31, 2007 in SEER
with follow up through December 31, 2010 in Medicare. The following patients were excluded: 1)
older than age 85 ; 2) with unknown urban category; 3) in hospital referral regions (HRR) with less
than 50 patients; 4) with unknown distance to the closest radiation facility; 5) patients who died
within the first 9 months of the study. A total of 31,541 patients were selected and categorized as
receiving androgen deprivation with or without radiation therapy.
The cohort was divided into the following three groups: 1) patients with American Joint Commission
on Cancer (AJCC) Tumor stage (T-stage) of T2 or T3 and aged 65-75 (called the “RCT Cohort”).
The patients in the “RCT Cohort“ are most comparable to the patients from the two randomized
studies of androgen deprivation with or without radiation therapy (Warde et al., 2011; Widmark
et al., 2009); 2) elderly patients under-represented or excluded from the published randomized
trials with T-stage T2 or T3, aged 76-85 (called the “Elderly Cohort“); and 3) patients with early
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stage, PSA-screen detected cancer with T-stage T1 disease who were excluded from the published
randomized trials (called the “Screen-Detected Cohort“).
The study by Widmark et al., 2009 included men from 47 centers in Europe diagnosed between
February, 1996 and December, 2002. 875 patients with locally advanced prostate cancer (T3; 78%;
prostate-specific antigen (PSA) ≤ 70 ng/mL; N0; M0) were enrolled. 439 patients were randomly
assigned to androgen deprivation alone and the other 436 patients received androgen deprivation
with radiation therapy. The study by Warde et. al. enrolled 1,205 patients with locally advanced
(T3 or T4) prostate cancer, organ-confined disease (T2) with either PSA >40 ng/mL or PSA >20
ng/mL and a Gleason score of 8 or higher between 1995 and 2005. 1205 patients were randomly
assigned to receive the androgen deprivation alone (n=602) or androgen deprivation with radiation
therapy (n=603). The hazard ratios for overall mortality reported previously (Widmark et al., 2009)
and (Warde et al., 2011) were 0.68 (95% CI 0.52—-0.89) and 0.77 (95% CI 0.61—-0.98). For ease
of comparison, we combined the results of the randomized trials using weighted-average meta-
analysis. The meta-analytic HR was 0.73 (0.61—-0.87).
To assess the effectiveness of androgen deprivation with or without radiation therapy in reducing
overall mortality (death from any cause), we performed two-stage IV Weibull regression analysis
(2SPS and 2SRI) using a local area treatment rate instrument and controlling for the propensity
score. The local area treatment rate instrument was defined as the proportion of patients who
received definitive treatment (surgery or radiation therapy) among all patients with prostate can-
cer in the hospital referral region (HRR) and we categorized this instrument into a binary variable
according to its median. This IV measures the ‘aggressiveness’ of local area treatment and cap-
tures regionally distinct structural care variation not fully explained by patient characteristics. The
IV was strongly associated with treatment assignment and balanced important prognostic factors
(Bekelman et al., 2015). The propensity score model included potential confounding variables in-
cluding age, race, ethnicity, clinical T stage, N stage, and World Health Organization tumor grade,
17 categories of co-morbid disease, urban residence, and census track median income.
As shown in Table 2.2, there is variability in the estimated HRs obtained from the 2SPS and 2SRI
methods. We estimated the shape parameter α ≈ 1.6 from the data. Using Figure 3, we can
see that the bias for both the 2SPS and 2SRI methods is the largest when we have an increasing
hazard (α > 1), even when the magnitude of unmeasured confounding is relatively small. When
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the hazard function is a decreasing one (α < 1), the 2SPS method produces more stable and less
biased estimates than the 2SRI method. In this case, 2SPS may be a more appropriate approach
to use. In the RCT Cohort, the estimated HRs (HR=0.96) from both IV methods are much larger
than the meta-analytic HR from the two randomized studies. Note that the confidence intervals
are also much larger in both IV analyses than in the original RCTs. In the published RCTs, the
authors concluded that there was a statistically significant treatment effect (combined therapy is
better) whereas from our IV analysis, we can’t draw this conclusion. In the total study sample and
separately in the RCT Cohort and the Screen-Detected Cohort, the two IV estimates are quite
similar. However, for the Elderly Cohort, the estimate from the 2SPS method is different from the
estimate from the 2SRI method.
2.7. Discussion
Many clinical and health services studies are using health care databases to compare the treat-
ment effectiveness for drug and surgical therapies, but are prone to unmeasured confounding. Two
stage IV methods have been gaining popularity among clinical researchers because these meth-
ods provide a relatively simple approach to analyzing survival outcome studies in the presence of
unmeasured confounding. However, current knowledge about potential bias in estimating the log
causal hazard ratio is limited. As demonstrated in our prostate cancer study, the large treatment
effects estimated from two stage IV methods could be attributable to potential bias. We have de-
rived closed-form expressions for the asymptotic bias of the 2SRI and 2SPS approaches assuming
the survival times follow a Weibull distribution with shape parameter α and scale parameter K. We
have demonstrated that these analytic results are consistent with our simulation results.
For binary outcomes, two previous studies (Cai, Small, and Ten Have, 2011; Ten Have, M, and
M., 2003) demonstrated that the bias in the treatment effect estimated using the 2SRI approach
increases as the magnitude of confounding increases. In this current work, we have shown an-
alytically and by simulation that the 2SRI and 2SPS approaches are both biased in estimating
the causal hazard ratio among compliers. In some situations when the hazard is decreasing (e.g
among patients who have recently received a kidney transplantation), the 2SPS method is less bi-
ased than the 2SRI method and could be a more appropriate method to use. When the hazard is an
increasing function, both IV methods may produce very large bias even under a moderate amount
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of unmeasured confounding. In this case, we recommend exercising caution when interpreting
results from two-stage IV survival models.
We have shown that even when all IV assumptions are met, both the 2SRI and the 2SPS methods
could fail to consistently estimate the causal hazard ratio among compliers. Our analytic results for
bias may help to guide researchers in deciding when the bias is likely to be reasonably small so that
two stage IV methods may be reasonably applied. Furthermore, in a sensitivity analysis approach,
one may estimate the shape parameter and the censoring proportion among patients assigned
to treatment or control from the data. With the shape parameter and censoring proportions fixed
based on our known data the level of the unmeasured confounding could be varied to examine
how the estimates would change, as shown in Figures 1 and 2. Alternative methods include partial
likelihood estimation (Cuzick et al., 2007).
2.8. Appendix
Appendix A: Mixture of Weibull Distributions
1) Prove the distribution function of observed survival time T conditional on random assignment R
can be expressed as the following equations:
F (T |R = 0) = 1− (e−(
t
θ1
AT
)α
ρA + e
−( t
θ0
NT
)α
ρN + e
−( t
θ0
C
)α
ρC) (A.1)
and,
F (T |R = 1) = 1− (e−(
t
θ1
C
)α
ρC + e
−( t
θ0
NT
)α
ρN + e
−( t
θ1
AT
)α
ρA) (A.2)
In the above equations, AT represents always takers, C represents compliers, and NT represents
never takers. Other definitions of parameters and distributions that are used in the proof are given
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below:
R = 1 if assigned to treatment;0 if assigned to control
Z = 1 if receives treatment; 0 if receives control
ρr = P (R = 1)
ρA = P (AT )
ρC = P (C)
ρN = 1− ρA − ρC
T 1 = potential outcome for a patient under treatment
T 0 = potential outcome for a patient under control
T 1|AT ∼ weibull(α, θ1AT )
T 1|C ∼ weibull(α, θ1C)
T 1|NT ∼ weibull(α, θ1NT )
T 0|AT ∼ weibull(α, θ0AT )
T 0|C ∼ weibull(α, θ0C)
T 0|NT ∼ weibull(α, θ0NT )
no defiers under monotonicity assumption
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Proof:
F (T (1)|Z = 1, R = 1) = P (T (1) ≤ t|Z = 1, R = 1)
=
P (T (1) ≤ t, Z = 1, R = 1)
P (Z = 1, R = 1)
=
P (T (1) ≤ t, AT,R = 1) + P (T (1) ≤ t, C,R = 1)
P (AT,R = 1) + P (C,R = 1)
=
P (T (1) ≤ t, AT )P (R = 1) + P (T (1) ≤ t, C)P (R = 1)
(P (AT ) + P (C))P (R = 1)
∵ R⊥(T (1), T (0)),
R⊥principal strata
=
P (T (1) ≤ t|AT )P (AT ) + P (T (1) ≤ t|C)P (C)
P (AT ) + P (C)
= (1− e−(
t
θ1
AT
)α
)
P (AT )
P (AT ) + P (C)
+ (1− e−(
t
θ1
C
)α
)
P (C)
P (AT ) + P (C)
F (T (0)|Z = 0, R = 1) = P (T (0) ≤ t|Z = 0, R = 1)
=
P (T (0) ≤ t, Z = 0, R = 1)
P (Z = 0, R = 1)
=
P (T (0) ≤ t,NT,R = 1)
P (NT )P (R = 1)
= P (T (0) ≤ t|NT ) ∵ R⊥(T (1), T (0)), R⊥principal strata
= (1− e−(
t
θ0
NT
)α
)
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F (T |R = 1)can be expressed as:
F (T |R = 1) = P (T ≤ t, Z = 1|R = 1) + P (T ≤ t, Z = 0|R = 1)
= P (T ≤ t|Z = 1, R = 1)P (Z = 1|R = 1)
+ P (T ≤ t|Z = 0, R = 0)P (Z = 0|R = 1)
= P (T (1) ≤ t|Z = 1, R = 1)P (Z = 1|R = 1)
+ P (T (0) ≤ t|Z = 0, R = 1)P (Z = 0|R = 1)
= ((1− e−(
t
θ1
AT
)α
)
P (AT )
P (AT ) + P (C)
+ (1− e−(
t
θ1
C
)α
)
P (C)
P (AT ) + P (C)
)(P (AT ) + P (C))
+ (1− e−(
t
θ0
NT
)α
)(P (NT ))
= 1− (e−(
t
θ1
C
)α
ρC + e
−( t
θ0
NT
)α
ρN + e
−( t
θ1
AT
)α
ρA)
F (T (1)|Z = 1, R = 0) = P (T (1) ≤ t|Z = 1, R = 0)
=
P (T (1) ≤ t, Z = 1, R = 0)
P (Z = 1, R = 0)
=
P (T (1) ≤ t, AT,R = 0)
P (AT,R = 0)
=
P (T (1) ≤ t|AT )P (AT )P (R = 0)
P (AT )P (R = 0)
= P (T (1) ≤ t|AT )
= 1− e−(
t
θ1
AT
)α
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F (T (0)|Z = 0, R = 0) = P (T (0) ≤ t|Z = 0, R = 0)
=
P (T (0) ≤ t, Z = 0, R = 0)
P (Z = 0, R = 0)
=
P (T (0) ≤ t,NT,R = 0) + P (T (0) ≤ t, C,R = 0)
P (NT,R = 0) + P (C,R = 0)
=
P (T (0) ≤ t|NT )P (NT ) + P (T (0) ≤ t|C)P (C)
P (NT ) + P (C)
= (1− e−(
t
θ0
NT
)α
)
P (NT )
P (NT ) + P (C)
+ (1− e−(
t
θ0
C
)α
)
P (C)
P (NT ) + P (C)
F (T |R = 0)can be expressed as:
F (T |R = 0) = P (T ≤ t, Z = 1|R = 0) + P (T ≤ t, Z = 0|R = 0)
= P (T ≤ t|Z = 1, R = 0)P (Z = 1|R = 0)
+ P (T ≤ t|Z = 0, R = 0)P (Z = 0|R = 0)
= P (T (1) ≤ t|Z = 1, R = 0)P (Z = 1|R = 0)
+ P (T (0) ≤ t|Z = 0, R = 0)P (Z = 0|R = 0)
= ((1− e−(
t
θ1
AT
)α
)P (AT )
+ [(1− e−(
t
θ0
NT
)α
)
P (NT )
P (NT ) + P (C)
+ (1− e−(
t
θ0
C
)α
)
P (C)
P (NT ) + P (C)
](P (C) + P (NT ))
= 1− (e−(
t
θ1
AT
)α
ρA + e
−( t
θ0
NT
)α
ρN + e
−( t
θ0
C
)α
ρC)
Appendix B: Proofs related with Derivation of Closed Form Solution
1) Assume survival time T ∼ Weibull(α,K) and censoring time L ∼ Weibull(α, λ). Let Y =
min(T, L) and δ = I(T ≤ L). Show that
Y ∼Weibull(α, ( 1λα + 1Kα )−1/α)
and,
P (δ = 1) =
1
1 + K
α
λα
(B.1)
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Proof:
P (Y ≥ y) = P (min(T, L) ≥ y)
= P (T ≥ y, L ≥ y)
=
∫ +∞
y
α
tα−1
Kα
exp(−( t
K
)α)dt
∫ +∞
y
α
lα−1
λα
exp(−( l
λ
)α)dl
= exp(−( y
K
)α)exp(−( y
λ
)α)
= exp(−( y
( 1λα +
1
Kα )
−1/α )
α)
Thus,Y ∼Weibull(α, ( 1λα + 1Kα )−1/α)
P (δ = 1) = P (0 ≤ T ≤ L, 0 ≤ L ≤ ∞)
=
∫ +∞
0
α
lα−1
λα
exp(−( l
λ
)α)
∫ l
0
α
tα−1
Kα
exp(−( t
K
)α)dtdl
=
∫ +∞
y
α
lα−1
λα
exp(−( l
λ
)α)[1− exp(−( l
K
)α)]dl
= 1−
∫ +∞
y
α
lα−1
λα
exp(−( l
λ
)α)exp(−( l
K
)α)dl
= 1− 1
1 + (λ/K)α
=
1
1 + (Kλ )
α
2) Assume survival time T is a mixture of three Weibull distributions with Density f(t) =
∑3
i=1 pif(ti).
T1 ∼ Weibull(α,K1), T2 ∼ Weibull(α,K2), and T3 ∼ Weibull(α,K3). The weights are p1, p2, p3
and
∑3
i=1 pi = 1. The censoring time L ∼ Weibull(α, λ). Let Y = min(T, L) and δ = I(T ≤ L).
Show that
P (δ = 1) = p1
1
1 +
Kα1
λα
+ p2
1
1 +
Kα2
λα
+ p3
1
1 +
Kα3
λα
(B.2)
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Proof:
P (δ = 1) = P (δ = 1, G = 1) + P (δ = 1, G = 2) + P (δ = 1, G = 3)
= P (δ = 1|G = 1)P (G = 1) + P (δ = 1|G = 2)P (G = 2) + P (δ = 1|G = 3)P (G = 3)
= p1
1
1 +
Kα1
λα
+ p2
1
1 +
Kα2
λα
+ p3
1
1 +
Kα3
λα
3) Given X follows a Weibull distribution (α∗,K). Show that
E(Xα) = Γ(
α
α∗
+ 1)Kα (B.3)
Proof:
E(Xα) =
∫
Xα
α∗
Kα∗
Xα
∗−1e−(
X
K )
α∗
dx
=
∫
y
α
α∗
1
Kα∗
e
− y
Kα
∗ dy Let y = xα
∗
=
1
Kα∗
∫
y(
α
α∗+1)−1e
− y
Kα
∗ dy
=
1
Kα∗
(Kα
∗
)(
α
α∗+1)Γ(
α
α∗
+ 1)
∫
1
(Kα∗)(
α
α∗+1)Γ( αα∗ + 1)
y(
α
α∗+1)−1e
− y
Kα
∗ dy
= Γ(
α
α∗
+ 1)Kα
4) Given X follows a Weibull distribution (α∗,K). Show that
E(log(X)) =
−γ
α∗
+ log(K) (B.4)
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Proof:
E(log(X)) =
∫ ∞
0
log(X)
α∗
Kα∗
Xα
∗−1e−(
X
K )
α∗
dx
=
∫
1
α∗
log(y)
1
Kα∗
e
− y
Kα
∗ dy Let y = xα
∗
=
∫
1
α∗
(log(u) + α∗log(K))e−udu Let y = uKα
∗
=
1
α∗
∫
log(u)e−udu︸ ︷︷ ︸
−γ
+log(K)
∫
e−udu Let y = uKα
∗
=
−γ
α∗
+ log(K)
5) Given X follows a Weibull distribution (α∗,K). Show that
E(Xαlog(X))
1
α∗
Γ(
α
α∗
+ 1)(Kα)(ψ(
α
α∗
+ 1) + α∗log(K)) (B.5)
Proof:
E(Xαlog(X)) =
∫ ∞
0
Xαlog(X)
α∗
Kα∗
Xα
∗−1e−(
X
K )
α∗
dx
=
∫
y
α
α∗
1
α∗
log(y)
1
Kα∗
e
− y
Kα
∗ dy Let y = xα
∗
=
1
α∗
1
Kα∗
Γ(
α
α∗
+ 1)(Kα
∗
)
α
α∗+1∫
log(y)
1
Γ( αα∗ + 1)(K
α∗)
α
α∗+1
y(
α
α∗+1)−1e
− y
Kα
∗ dy︸ ︷︷ ︸
E(log(y))
y ∼ gamma( α
α∗
+ 1,Kα
∗
)
=
1
α∗
1
Kα∗
Γ(
α
α∗
+ 1)(Kα
∗
)
α
α∗+1(ψ(
α
α∗
+ 1) + α∗log(K)) ψ() is digamma function
=
1
α∗
Γ(
α
α∗
+ 1)(Kα)(ψ(
α
α∗
+ 1) + α∗log(K))
6) Let Ti denote the survival time and Ci denote the censoring time for subject i. Ti and Ci are
independent. Ti ∼ weibull(α,K), and Ci ∼ weibull(α, λ). Let Yi = min(Ti, Ci) denote observed
follow-up time and δi be the indicator variable δi = (Ti ≤ Ci). Show that:
E(Yiδi) = E(Yi)E(δi) (B.6)
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Proof:
E(Yiδi) = E(Yiδi(I(δi = 1) + I(δi = 0))
= E(YiδiI(δi = 1)) + E(YiδiI(δi = 0))
= E(TiI(δi = 1))
=
∫ ∞
0
∫ ∞
0
tI(δi = 1)f(t, c)dtdc
=
∫ ∞
0
∫ ∞
0
tI(t ≤ c)ft(t)fc(c)dtdc
=
∫ ∞
0
{
∫ ∞
0
I(t ≤ c)fc(c)dc}tft(t)dt
=
∫ ∞
0
Sc(t)tft(t)dt
=
∫ ∞
0
t exp
(
− t
α
λα
)
α
Kα
tα−1 exp
(
− t
α
Kα
)
dt
Let K∗ = ( 1λα +
1
Kα )
−1/α and use (B.1)
E(Yi)E(δi) = (
1
1 + K
α
λα
)
∫ ∞
0
y
α
K∗α
yα−1 exp
(
− y
α
K∗α
)
dy
=
∫ ∞
0
α
Kα
yα−1 exp
(
− y
α
Kα
)
y exp
(
− y
α
λα
)
dy
Both E(Yiδi) and E(Yi)E(δi) have the same integral functions. Thus,
E(Yiδi) = E(Yi)E(δi)
Similarly, we can establish the following:
E(g(Yi)δi) = E(g(Yi))E(δi)
Appendix C: Derivation of probability limits of M.L.E of α,K0,K1 for 2SPS
Let Y = min(T,C) be observed follow-up time and δ = I(T ≤ C) be the censoring time. The
subjects are assigned to either treatment group (R = 1) or control group (R = 0). The distribution of
each subgroup has different scale parameter K but the same shape parameter α∗. Thus, likelihood
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function of observed follow up time Y can be written as:
L(y) =
nR1∏
i∈{R=1}
[(α∗/K1)(yi/K1)
α∗−1]δi [exp(−(yi/K1)α
∗
)]
×
nR0∏
i∈{R=0}
[(α∗/K0)(yi/K0)
α∗−1]δi [exp(−(yi/K0)α
∗
)]
For treatment assignment group and control assignment group, subjects are from compliers (c),
never takers(nt),and always takers(at). Let nR1 , nR0 denote number of subjects assigned to treat-
ment (R = 1) and control(R = 0). Let nR1,at, nR1,nt, nR1,c denote number of always takers, never
takers, and compliers that are assigned to treatment group.nR1,at + nR1,nt + nR1,c = nR1 . Let
nR0,at, nR0,nt, nR0,c denote number of always takers, never takers, and compliers, who are assigned
to control group.nR0,at + nR0,nt + nR0,c = nR0 . Therefore, the likelihood can be rewritten as:
L(y) =
nR1,at∏
i∈{R=1,at}
[(α∗/K1)(yi/K1)
α∗−1]δi [exp(−(yi/K1)α
∗
)]
×
nR1,c∏
i∈{R=1,c}
[(α∗/K1)(yi/K1)
α∗−1]δi [exp(−(yi/K1)α
∗
)]
×
nR1,nt∏
i∈{R=1,nt}
[(α∗/K1)(yi/K1)
α∗−1]δi [exp(−(yi/K1)α
∗
)]
×
nR0,at∏
i∈{R=0,at}
[(α∗/K0)(yi/K0)
α∗−1]δi [exp(−(yi/K0)α
∗
)]
×
nR0,c∏
i∈{R=0,c}
[(α∗/K0)(yi/K0)
α∗−1]δi [exp(−(yi/K0)α
∗
)]
×
nR0,nt∏
i∈{R=0,nt}
[(α∗/K0)(yi/K0)
α∗−1]δi [exp(−(yi/K0)α
∗
)]
Next, the log likelihood function is:
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l(y) =
nR1,at∑
i∈{R=1,at}
δi{log(α∗)− log(K1)) + (α∗ − 1)(log(yi)− log(K1))}
+
nR1,c∑
i∈{R=1,c}
δi{log(α∗)− log(K1)) + (α∗ − 1)(log(yi)− log(K1))}
+
nR1,nt∑
i∈{R=1,nt}
δi{log(α∗)− log(K1)) + (α∗ − 1)(log(yi)− log(K1))}
+
nR1∑
i∈{R=1}
−(yi/K1)α
∗
+
nR0,at∑
i∈{R=0,at}
δi{log(α∗)− log(K0)) + (α∗ − 1)(log(yi)− log(K0))}
+
nR0,c∑
i∈{R=0,c}
δi{log(α∗)− log(K0)) + (α∗ − 1)(log(yi)− log(K0))}
+
nR0,nt∑
i∈{R=0,nt}
δi{log(α∗)− log(K0)) + (α∗ − 1)(log(yi)− log(K0))}
+
nR0∑
i∈{R=0}
−(yi/K0)α
∗
To derive the M.L.E of K0,K1, take the first derivative of l(y) with respect to K0,K1 and set score
equation to 0, we have
K̂0 = [
∑nR0
i∈{R=0} y
α∗
i∑nR0
i∈{R=0} δi
]1/α
∗
(C.1)
and,
K̂1 = [
∑nR1
i∈{R=1} y
α∗
i∑nR1
i∈{R=1} δi
]1/α
∗
(C.2)
To derive the M.L.E of α∗, take the first derivative of l(y) with respect to α∗ and set score equation
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to 0 and replace K1,K0 with the expressions (C.1) and (C.2), we have
0 =
∑nR0
i∈{R=0} δi
α∗
+
nR0,at∑
i∈{R=0,at}
δilog(yi) +
nR0,c∑
i∈{R=0,c}
δilog(yi) +
nR0,nt∑
i∈{R=0,nt}
δilog(yi)
− {
nR0∑
i∈{R=0}
δi}
∑nR0
i∈{R=0} y
α∗
i log(yi)∑nR0
i∈{R=0} y
α∗
i
+
∑nR1
i∈{R=1} δi
α∗
+
nR1,at∑
i∈{R=1,at}
δilog(yi) +
nR1,c∑
i∈{R=1,c}
δilog(yi) +
nR1,nt∑
i∈{R=1,nt}
δilog(yi)
− {
nR1∑
i∈{R=1}
δi}
∑nR1
i∈{R=1} y
α∗
i log(yi)∑nR1
i∈{R=1} y
α∗
i
=
∑nR0
i∈{R=0} δi
α∗
+
nR0,at∑
i∈{R=0,at}
δilog(yi) +
nR0,c∑
i∈{R=0,c}
δilog(yi) +
nR0,nt∑
i∈{R=0,nt}
δilog(yi)
− {
nR0∑
i∈{R=0}
δi}
∑nR0,at
i∈{R=0,at} y
α∗
i log(yi) +
∑nR0,c
i∈{R=0,c} y
α∗
i log(yi) +
∑nR0,nt
i∈{R=0,nt} y
α∗
i log(yi)∑nR0,at
i∈{R=0,at} y
α∗
i +
∑nR0,c
i∈{R=0,c} y
α∗
i +
∑nR0,nt
i∈{R=0,nt} y
α∗
i
+
∑nR1
i∈{R=1} δi
α∗
+
nR1,at∑
i∈{R=1,at}
log(yi) +
nR1,c∑
i∈{R=1,c}
log(yi) +
nR1,nt∑
i∈{R=1,nt}
log(yi)
− {
nR1∑
i∈{R=1}
δi}
∑nR1,at
i∈{R=1,at} y
α∗
i log(yi) +
∑nR1,c
i∈{R=1,c} y
α∗
i log(yi) +
∑nR1,nt
i∈{R=1,nt} y
α∗
i log(yi)∑nR1,at
i∈{R=1,at} y
α∗
i +
∑nR1,c
i∈{R=1,c} y
α∗
i +
∑nR1,nt
i∈{R=1,nt} y
α∗
i
M.L.E α̂∗ is the solution to the above equation. Next, divide both sides by total number of subject
n, we have
0 =
∑nR0
i∈{R=0} δi/nR0
α∗
nR0
n
+ {
nR0,at∑
i∈{R=0,at}
δilog(yi) +
nR0,c∑
i∈{R=0,c}
δilog(yi) +
nR0,nt∑
i∈{R=0,nt}
δilog(yi)}/nR0
nR0
n
−
nR0
n
{
nR0∑
i∈{R=0}
δi/nR0}
{
∑nR0,at
i∈{R=0,at} y
α∗
i log(yi) +
∑nR0,c
i∈{R=0,c} y
α∗
i log(yi) +
∑nR0,nt
i∈{R=0,nt} y
α∗
i log(yi)}/nR0
{
∑nR0,at
i∈{R=0,at} y
α∗
i +
∑nR0,c
i∈{R=0,c} y
α∗
i +
∑nR0,nt
i∈{R=0,nt} y
α∗
i }/nR0
+
∑nR1
i∈{R=1} δi/nR1
α∗
nR1
n
+ {
nR1,at∑
i∈{R=1,at}
δilog(yi) +
nR1,c∑
i∈{R=1,c}
δilog(yi) +
nR1,nt∑
i∈{R=1,nt}
δilog(yi)}/nR1
nR1
n
−
nR1
n
{
nR1∑
i∈{R=1}
δi/nR1}
{
∑nR1,at
i∈{R=1,at} y
α∗
i log(yi) +
∑nR1,c
i∈{R=1,c} y
α∗
i log(yi) +
∑nR1,nt
i∈{R=1,nt} y
α∗
i log(yi)}/nR1
{
∑nR1,at
i∈{R=1,at} y
α∗
i +
∑nR1,c
i∈{R=1,c} y
α∗
i +
∑nR1,nt
i∈{R=1,nt} y
α∗
i }/nR1
As nR1 , nR0 , nR1,at, nR1,nt, nR1,c, nR0,at, nR0,nt, nR0,c → ∞, the score equation converges to the
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following:
0 = P (δ = 1|R = 0)P (R = 0)/α∗
+ P (R = 0){P (AT )E(δlog(Y )|at,R = 0) + P (C)E(δlog(Y )|c,R = 0) + P (NT )E(δlog(Y )|nt,R = 0)}
− P (δ = 1|R = 0)P (R = 0)
× {P (AT )E(Y
α∗ log(Y )|at,R = 0) + P (C)E(Y α
∗
log(Y )|c,R = 0) + P (NT )E(Y α
∗
log(Y )|nt,R = 0)}
{P (AT )E(Y α∗ |at,R = 0) + P (C)E(Y α∗ |c,R = 0)) + P (NT )E(Y α∗ |nt,R = 0)}
+ P (δ = 1|R = 1)P (R = 1)/α∗
+ P (R = 1){P (AT )E(δlog(Y )|at,R = 1) + P (C)E(δlog(Y )|c,R = 1) + P (NT )E(δlog(Y )|nt,R = 1)}
− P (δ = 1|R = 1)P (R = 1)
× {P (AT )E(Y
α∗ log(Y )|at,R = 1) + P (C)E(Y α
∗
log(Y )|c,R = 1) + P (NT )E(Y α
∗
log(Y )|nt,R = 1)}
{P (AT )E(Y α∗ |at,R = 1) + P (C)E(Y α∗ |c,R = 1)) + P (NT )E(Y α∗ |nt,R = 1)}
(C.3)
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Use the results from Appendix B, we can derive the following:
E(δlog(Y )|at,R = 0) = P (δ = 1|at,R = 0)(−γ
α
+ log([
1
θ1at
α +
1
λα
]−1/α))
=
1
1 +
θ1at
α
λα
(
−γ
α
+ log([
1
θ1at
α +
1
λα
]−1/α)
E(δlog(Y )|nt,R = 0) = P (δ = 1|nt,R = 0)(−γ
α
+ log([
1
θ0nt
α +
1
λα
]−1/α))
=
1
1 +
θ0nt
α
λα
(
−γ
α
+ log([
1
θ0nt
α +
1
λα
]−1/α))
E(δlog(Y )|c,R = 0) = P (δ = 1|c,R = 0)(−γ
α
+ log([
1
θ0c
α +
1
λα
]−1/α))
=
1
1 +
θ0c
α
λα
(
−γ
α
+ log([
1
θ0c
α +
1
λα
]−1/α))
E(Y α
∗
log(Y )|at,R = 0) = (ψ(α
∗
α
+ 1) + αlog([
1
θ1at
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
log(Y )|nt,R = 0) = (ψ(α
∗
α
+ 1) + αlog([
1
θ0nt
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
log(Y )|c,R = 0) = (ψ(α
∗
α
+ 1) + αlog([
1
θ0c
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ0c
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
|at,R = 0) = Γ(α
∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α
∗/α
E(Y α
∗
|nt,R = 0) = Γ(α
∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α
E(Y α
∗
|c,R = 0) = Γ(α
∗
α
+ 1)[
1
θ0c
α +
1
λα
]−α
∗/α
P (δ = 1|R = 0) = Pat
1
1 +
θ1at
α
λα
+ Pnt
1
1 +
θ0nt
α
λα
+ Pc
1
1 +
θ0c
α
λα
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and,
E(δlog(Y )|at,R = 1) = P (δ = 1|at,R = 1)(−γ
α
+ log([
1
θ1at
α +
1
λα
]−1/α))
=
1
1 +
θ1at
α
λα
(
−γ
α
+ log([
1
θ1at
α +
1
λα
]−1/α))
E(δlog(Y )|nt,R = 1) = P (δ = 1|nt,R = 1)(−γ
α
+ log([
1
θ0nt
α +
1
λα
]−1/α)))
=
1
1 +
θ0nt
α
λα
(
−γ
α
+ log([
1
θ0nt
α +
1
λα
]−1/α))
E(δlog(Y )|c,R = 1) = P (δ = 1|c,R = 1)(−γ
α
+ log([
1
θ1c
α +
1
λα
]−1/α))
=
1
1 +
θ1c
α
λα
(
−γ
α
+ log([
1
θ1c
α +
1
λα
]−1/α))
E(Y α
∗
log(Y )|at,R = 1) = (ψ(α
∗
α
+ 1) + αlog([
1
θ1at
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
log(Y )|nt,R = 1) = (ψ(α
∗
α
+ 1) + αlog([
1
θ0nt
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
log(Y )|c,R = 1) = (ψ(α
∗
α
+ 1) + αlog([
1
θ1c
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ1c
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
|at,R = 1) = Γ(α
∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α
∗/α
E(Y α
∗
|nt,R = 1) = Γ(α
∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α
E(Y α
∗
|c,R = 1) = Γ(α
∗
α
+ 1)[
1
θ1c
α +
1
λα
]−α
∗/α
P (δ = 1|R = 1) = Pat
1
1 +
θ1at
α
λα
+ Pnt
1
1 +
θ0nt
α
λα
+ Pc
1
1 +
θ1c
α
λα
Let α̃∗ be the solution to the equation (C.3). By the consistency of M.L.E, Thus, we have α̂∗ P−→ α̃∗
Next, substitute α̂∗ into equation (C.1)
K̂0 = [
∑nR0
i∈{R=0} y
α̂∗
i∑nR0
i∈{R=0} δi
]1/α̂
∗
= [
nR0∑nR0
i∈{R=0} δi
{
nR0,at∑
i∈{R=0,at}
yα̂
∗
i +
nR0,nt∑
i∈{R=0,nt}
yα̂
∗
i +
nR0,c∑
i∈{R=0,c}
yα̂
∗
i }/nR0 ]1/α̂
∗
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Asymptotically, it converges to
K̂0 → [
1
P (δ = 1|R = 0){PatE(Y
α̃∗
at,0) + PntE(Y
α̃∗
nt,0) + PcE(Y
α̃∗
c,0 )}]1/α̃
∗
= [
1
P (δ = 1|R = 0)×
{PatΓ(
α̃∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α̃
∗/α + PntΓ(
α̃∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α̃
∗/α + PcΓ(
α̃∗
α
+ 1)[
1
θ0c
α +
1
λα
]−α̃
∗/α}]1/α̃∗
Similarly, K̂1 converges to
K̂1 → [
1
P (δ = 1|R = 1)×
{PatΓ(
α̃∗
α
+ 1)[
1
θ1at
α +
1
λα
]−α̃
∗/α + PntΓ(
α̃∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α̃
∗/α + PcΓ(
α̃∗
α
+ 1)[
1
θ1c
α
+
1
λα
]−α̃
∗/α}]1/α̃∗
Appendix D: Derivation of probability limits of M.L.E of α,K0,K1,K2 for 2SRI
Under the no AT assumption, we can find an expression for λ1 as follows. The first stage regression
can be re-expressed as following:
E(Z|R) = ρAT + ρCR
E = Z − E(Z|R)
= Z − ρA − ρCR
Note that Z,E and Z,R are one-to-one correspondence. Knowing Z,E will let us know Z,R and
vice versa. Under no always taker assumption, we observe three subgroups 1)Z = 1, R = 1. Only
compliers in this group; 2) Z = 0, R = 1, Only never takers in this group; 3)Z = 0, R = 0, both
never takers and compliers in this group. There are no patients that are assigned to control but still
takes on active treatment (Z = 1, R = 0). For the 3 subgroups, essentially we are fitting 3 Weibull
distributions with the same shape parameter α∗ and 3 different shape parameter K0,K1,K2 with
Weibull regression model: logh(t) = λ0 + λ1Z + λ2E
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The likelihood function is:
L(y) =
nZ1,R1,c∏
i∈{Z=1,R=1,c}
[(α∗/K0)(yi/K0)
α∗−1]δi [exp(−(yi/K0)α
∗
)]
×
nZ0,R1,nt∏
i∈{Z=0,R=1,nt}
[(α∗/K1)(yi/K1)
α∗−1]δi [exp(−(yi/K1)α
∗
)]
×
nZ0,R0,nt∏
i∈{Z=0,R=0,nt}
[(α∗/K2)(yi/K2)
α∗−1]δi [exp(−(yi/K2)α
∗
)]
×
nZ0,R0,c∏
i∈{Z=0,R=0,c}
[(α∗/K2)(yi/K2)
α∗−1]δi [exp(−(yi/K2)α
∗
)]
The log likelihood is:
l(y) =
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δi{log(α∗)− log(K0)) + (α∗ − 1)(log(yi)− log(K0))}+
nZ1,R1,c∑
i∈{Z=1,R=1,c}
−(yi/K0)α
∗
+
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δi{log(α∗)− log(K1)) + (α∗ − 1)(log(yi)− log(K1))}+
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
−(yi/K1)α
∗
+
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δi{log(α∗)− log(K2)) + (α∗ − 1)(log(yi)− log(K2))}+
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
−(yi/K2)α
∗
+
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δi{log(α∗)− log(K2)) + (α∗ − 1)(log(yi)− log(K2))}+
nZ0,R0,c∑
i∈{Z=0,R=0,c}
−(yi/K2)α
∗
Take the first derivative of l(y) with respective to K0,K1,K2 respectively and set score equation to
0, then we have
K̂0 = [
∑nZ1,R1,c
i∈{Z=1,R=1,c} y
α∗
i∑nZ1,R1,c
i∈{Z=1,R=1,c} δi
]1/α
∗
(D.1)
K̂1 = [
∑nZ0,R1,nt
i∈{Z=0,R=1,nt} y
α∗
i∑nZ0,R1,nt
i∈{Z=0,R=1,nt} δi
]1/α
∗
(D.2)
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K̂2 = [
∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α∗
i +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α∗
i∑nZ0,R0,nt
i∈{Z=0,R=0,nt} δi +
∑nZ0,R0,c
i∈{Z=0,R=0,c} δi
]1/α
∗
(D.3)
Take the first derivative of l(y) with respective to α∗ and replace K0,K1,K2 with expression (D.1) ,
(D.2) , (D.3), then we have:
dlog(L(y))
dα
=
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δi{
1
α∗
+ log(yi)} −
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δi
∑nZ1,R1,c
i∈{Z=1,R=1,c}(yi)
α∗ log(yi)∑nZ1,R1,c
i∈{Z=1,R=1,c}(yi)
α∗
+
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δi{
1
α∗
+ log(yi)} −
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δi
∑nZ0,R1,nt
i∈{Z=0,R=1,nt}(yi)
α∗ log(yi)∑nZ0,R1,nt
i∈{Z=0,R=1,nt}(yi)
α∗
+
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δi{
1
α∗
+ log(yi)}+
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δi{
1
α∗
+ log(yi)}
− (
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δi +
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δi)
∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α∗
i log(yi) +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α∗
i log(yi)∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α∗
i +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α∗
i
=
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δi
1
α∗
+
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δilog(yi)−
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δi
∑nZ1,R1,c
i∈{Z=1,R=1,c}(yi)
α∗ log(yi)∑nZ1,R1,c
i∈{Z=1,R=1,c}(yi)
α∗
+
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δi
1
α∗
+
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δilog(yi)−
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δi
∑nZ0,R1,nt
i∈{Z=0,R=1,nt}(yi)
α∗ log(yi)∑nZ0,R1,nt
i∈{Z=0,R=1,nt}(yi)
α∗
+
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δi
1
α∗
+
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δilog(yi) +
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δi
1
α∗
+
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δilog(yi)
− (
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δi +
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δi)
∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α∗
i log(yi) +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α∗
i log(yi)∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α∗
i +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α∗
i
= 0
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M.L.E α̂∗ is the solution to the above score equation. Next, divide the equation by total sample size n,
0 =
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δi
1
α∗
/nZ1,R1,c ×
nZ1,R1,c
n
+
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δilog(yi)/nZ1,R1,c ×
nZ1,R1,c
n
− (
nZ1,R1,c∑
i∈{Z=1,R=1,c}
δi/nZ1,R1,c ×
nZ1,R1,c
n
)
∑nZ1,R1,c
i∈{Z=1,R=1,c}(yi)
α∗ log(yi)/nZ1,R1,c∑nZ1,R1,c
i∈{Z=1,R=1,c}(yi)
α∗/nZ1,R1,c
+
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δi
1
α∗
/nZ0,R1,nt ×
nZ0,R1,nt
n
+
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δilog(yi)/nZ0,R1,nt ×
nZ0,R1,nt
n
− (
nZ0,R1,nt∑
i∈{Z=0,R=1,nt}
δi/nZ0,R1,nt ×
nZ0,R1,nt
n
)
∑nZ0,R1,nt
i∈{Z=0,R=1,nt}(yi)
α∗ log(yi)/nZ0,R1,nt∑nZ0,R1,nt
i∈{Z=0,R=1,nt}(yi)
α∗/nZ0,R1,nt
+ {
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δi
1
α∗
+
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δilog(yi)}/nZ0,R0,nt ×
nZ0,R0,nt
n
+ {
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δi
1
α∗
+
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δilog(yi)}/nZ0,R0,c ×
nZ0,R0,c
n
− (
nZ0,R0,nt∑
i∈{Z=0,R=0,nt}
δi +
nZ0,R0,c∑
i∈{Z=0,R=0,c}
δi)/nZ0,R0 ×
nZ0,R0
n
×
{
∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α∗
i log(yi) +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α∗
i log(yi)}/nZ0,R0
{
∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α∗
i +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α∗
i }/nZ0,R0
As sample sizes in each principal strata→∞, the score equation will converge to:
0 =
1
α∗
P (δ = 1|Z = 1, R = 1)P (Z = 1, R = 1) + E(δlog(y)|Z = 1, R = 1)P (Z = 1, R = 1)
− P (δ = 1|Z = 1, R = 1)P (Z = 1, R = 1)E(Y
α∗ log(Y )|Z = 1, R = 1))
E(Y α∗ |Z = 1, R = 1)
+
1
α∗
P (δ = 1|Z = 0, R = 1)P (Z = 0, R = 1) + E(δlog(y)|Z = 0, R = 1)P (Z = 0, R = 1)
− P (δ = 1|Z = 0, R = 1)P (Z = 0, R = 1)E(Y
α∗ log(Y )|Z = 0, R = 1))
E(Y α∗ |Z = 0, R = 1)
+
1
α∗
P (δ = 1|Z = 0, R = 0, nt)P (Z = 0, R = 0, nt) + E(δlog(y)|Z = 0, R = 0, nt)P (Z = 0, R = 0, nt)
+
1
α∗
P (δ = 1|Z = 0, R = 0, c)P (Z = 0, R = 0, c) + E(δlog(y)|Z = 0, R = 0, c)P (Z = 0, R = 0, c)
− ( Pnt
Pnt + Pc
P (δ = 1|Z = 0, R = 0, nt) + Pc
Pnt + Pc
P (δ = 1|Z = 0, R = 0, c))
× (P (Z = 0, R = 0, nt) + P (Z = 0, R = 0, c))
× P (nt)E(Y
α∗ log(Y )|Z = 0, R = 0, nt) + P (c)E(Y α
∗
log(Y )|Z = 0, R = 0, c)
P (nt)E(Y α∗ |Z = 0, R = 0, nt) + P (c)E(Y α∗ |Z = 0, R = 0, c) (D.4)
41
where,
P (δ = 1|Z = 1, R = 1) = 1
1 + (
θ1c
λ
)α
P (Z = 1, R = 1) = P (C,R = 1)
= PcP (R = 1)
E(δlog(y)|Z = 1, R = 1) = 1
1 +
θ1c
α
λα
(
−γ
α
+ log([
1
θ1c
α +
1
λα
]−1/α))
E(Y α
∗
log(Y )|Z = 1, R = 1) = (ψ(α
∗
α
+ 1) + αlog([
1
θ1c
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ1c
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
|Z = 1, R = 1) = Γ(α
∗
α
+ 1)[
1
θ1c
α +
1
λα
]−α
∗/α
P (δ = 1|Z = 0, R = 1) = 1
1 + (
θ0nt
λ
)α
P (Z = 0, R = 1) = P (nt,R = 1)
= PntP (R = 1)
E(δlog(y)|Z = 0, R = 1) = 1
1 +
θ0nt
α
λα
(
−γ
α
+ log([
1
θ0nt
α +
1
λα
]−1/α))
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E(Y α
∗
log(Y )|Z = 0, R = 1) = (ψ(α
∗
α
+ 1) + αlog([
1
θ0nt
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
|Z = 0, R = 1) = Γ(α
∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α
P (δ = 1|Z = 0, R = 0, nt) = 1
1 + (
θ0nt
λ
)α
P (Z = 0, R = 0, nt) = P (nt,R = 0)
= PntP (R = 0)
E(δlog(y)|Z = 0, R = 0, nt) = 1
1 +
θ0nt
α
λα
(
−γ
α
+ log([
1
θ0nt
α +
1
λα
]−1/α))
E(Y α
∗
log(Y )|Z = 0, R = 0, nt) = (ψ(α
∗
α
+ 1) + αlog([
1
θ0nt
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
|Z = 0, R = 0, nt) = Γ(α
∗
α
+ 1)[
1
θ0nt
α +
1
λα
]−α
∗/α
P (δ = 1|Z = 0, R = 0, c) = 1
1 + (
θ0c
λ
)α
P (Z = 0, R = 0, c) = P (c,R = 0)
= PcP (R = 0)
E(δlog(y)|Z = 0, R = 0, c) = 1
1 +
θ0c
α
λα
(
−γ
α
+ log([
1
θ0c
α +
1
λα
]−1/α))
E(Y α
∗
log(Y )|Z = 0, R = 0, c) = (ψ(α
∗
α
+ 1) + αlog([
1
θ0c
α +
1
λα
]−1/α))Γ(
α∗
α
+ 1)[
1
θ0c
α +
1
λα
]−α
∗/α 1
α
E(Y α
∗
|Z = 0, R = 0, c) = Γ(α
∗
α
+ 1)[
1
θ0c
α +
1
λα
]−α
∗/α
α̃∗ is the solution to the equation (D.4). Thus, α̂∗ → α̃∗. Probability limits of M.L.E of K0 can be
derived as following:
K̂0 = [
∑nZ1,R1,c
i∈{Z=1,R=1,c} y
α̂∗
i∑nZ1,R1,c
i∈{Z=1,R=1,c} δi
]1/α̂
∗
= [
∑nZ1,R1,c
i∈{Z=1,R=1,c} y
α̂∗
i /nZ1,R1,c∑nZ1,R1,c
i∈{Z=1,R=1,c} δi/nZ1,R1,c
]1/α̂
∗
→ [ E(y
α̃∗
i |Z = 1, R = 1, c)
P (δ = 1|Z = 1, R = 1, c) ]
1/α̃∗
= [
Γ( α̃
∗
α + 1)[
1
θ1c
α + 1λα ]
−α̃∗/α
1
1+(
θ1c
λ )
α
]1/α̃
∗
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Similarly, for K1,K2,
K̂1 = [
∑nZ0,R1,nt
i∈{Z=0,R=1,nt} y
α̂∗
i∑nZ0,R1,nt
i∈{Z=0,R=1,nt} δi
]1/α̂
∗
→ [
Γ( α̃
∗
α + 1)[
1
θ0nt
α + 1λα ]
−α̃∗/α
1
1+(
θ0nt
λ )
α
]1/α̃
∗
K̂2 = [
∑nZ0,R0,nt
i∈{Z=0,R=0,nt} y
α̂∗
i +
∑nZ0,R0,c
i∈{Z=0,R=0,c} y
α̂∗
i∑nZ0,R0,nt
i∈{Z=0,R=0,nt} δi +
∑nZ0,R0,c
i∈{Z=0,R=0,c} δi
]1/α̂
∗
→ [
Γ( α̃
∗
α + 1)[
1
θ0nt
α + 1λα ]
−α̃∗/α Pnt
Pnt+Pc
+ Γ( α̃
∗
α + 1)[
1
θ0c
α + 1λα ]
−α̃∗/α Pc
Pnt+Pc
1
1+(
θ0nt
λ )
α
Pnt
Pnt+Pc
+ 1
1+(
θ0c
λ )
α
Pc
Pnt+Pc
]1/α̃
∗
Appendix E: Assumption of the same shape parameter for survival and censoring distributions
In section 2 of the manuscript, we made the assumption that both time to event and censoring
time have the same shape parameter so that close form solution could be derived. To evaluate the
potential impact on the bias when the time to event and censoring time have two different shape
parameters and the assumption is violated, we re-evaluated the scenario in the table 1 with the
shape parameter α = 0.5. We set the shape parameter of censoring distribution to be 1.2 and
compared the differences. We found that the differences in bias of 2SPS between two scenarios
ranges from 0.01 to 0.018 (δ varies from -2 to 2). For 2SRI approach, the differences ranges from
0.001 to 0.13. These differences are attributable to the different censoring proportions between two
scenarios. The shape of relationship between bias and δ remains approximately unchanged(data
not shown). It should be noted that under the assumption of having the same shape parameters
for both survival time and censoring time, the maximum likelihood estimator based on the survival
likelihood that does not incorporate the assumption of the shape parameters being the same is not
fully efficient.
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Figure 2.1: Plot of bias against magnitude of unmeasured confounding ∆ using 2SPS
method:(a)P (R = 1) = 0.8, ρa = 0, ρc = 0.5, θ1c = 3.33, θ0c = 1.67.(b)P (R = 1) = 0.8,
ρa = 0, ρc = 0.8, θ1c = 3.33, θ0c = 1.67.(c) P (R = 1) = 0.8, ρa = 0, ρc = 0.5, θ1c = 33.3,
θ0c = 16.7. (d) P (R = 1) = 0.5, ρa = 0, ρc = 0.8, θ1c = 3.33, θ0c = 1.67. The different
colour of solid line corresponds to different shape parameter: black (α = 0.5),red
(α = 1),and green (α = 2).
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Figure 2.2: Plot of bias against magnitude of unmeasured confounding ∆ using 2SRI
method:(a)P (R = 1) = 0.8, ρa = 0, ρc = 0.5, θ1c = 3.33, θ0c = 1.67.(b)P (R = 1) = 0.8,
ρa = 0, ρc = 0.8, θ1c = 3.33, θ0c = 1.67.(c) P (R = 1) = 0.8, ρa = 0, ρc = 0.5, θ1c = 33.3,
θ0c = 16.7. (d) P (R = 1) = 0.5, ρa = 0, ρc = 0.8, θ1c = 3.33, θ0c = 1.67. The different
colour of solid line corresponds to different shape parameter: black (α = 0.5),red
(α = 1),and green (α = 2).
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Figure 2.3: Absolute bias in estimating log causal hazard ratio using two stage IV
methods (X-axis is the magnitude of confounding ∆ , Y-axis is the absolute bias).
For 2SRI method or 2SPS method, the biases computed for each of 1458 possible
scenarios were grouped by the magnitude of shape parameter α (decreasing hazard
for α = 0.5, constant hazard for α = 1, and increasing hazard for α = 2) and the
magnitude of confounding ∆ (larger values represent lager confounding effects and 0
represents no confounding).
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Table 2.1: Bias in estimating log causal hazard ratio parameter ( ρa = 0, ρc = 0.5, ρr =
0.8, θ1c = 3.33, θ
0
c = 1.67)
α δ Biasanalytic2sps Bias
AFT
2sps Bias
Cox
2sps Bias
analytic
2sri Bias
AFT
2sri Bias
Cox
2sri
0.5 2 -0.094 -0.093 -0.091 -0.477 -0.476 -0.476
1.5 -0.067 -0.068 -0.064 -0.238 -0.239 -0.235
1 -0.039 -0.040 -0.039 -0.086 -0.087 -0.086
0.5 -0.013 -0.016 -0.012 -0.015 -0.018 -0.014
0 0.007 0.009 0.007 0.000 0.002 0.000
-0.5 0.023 0.020 0.026 0.000 -0.003 -0.001
-1 0.038 0.037 0.051 0.029 0.028 0.029
-1.5 0.055 0.053 0.075 0.114 0.112 0.108
-2 0.073 0.074 0.101 0.261 0.263 0.236
1 2 -0.250 -0.253 -0.247 -0.545 -0.550 -0.544
1.5 -0.177 -0.175 -0.177 -0.285 -0.284 -0.284
1 -0.096 -0.093 -0.097 -0.110 -0.107 -0.112
0.5 -0.017 -0.020 -0.018 -0.022 -0.025 -0.023
0 0.051 0.053 0.055 0.000 0.002 0.000
-0.5 0.107 0.106 0.116 -0.007 -0.008 -0.009
-1 0.152 0.153 0.177 0.000 0.000 0.002
-1.5 0.193 0.191 0.232 0.057 0.053 0.055
-2 0.230 0.232 0.280 0.175 0.176 0.157
1.5 2 -0.422 -0.423 -0.418 -0.605 -0.607 -0.602
1.5 -0.285 -0.285 -0.284 -0.326 -0.325 -0.326
1 -0.132 -0.133 -0.134 -0.133 -0.134 -0.134
0.5 0.019 0.023 0.021 -0.028 -0.027 -0.029
0 0.153 0.152 0.159 0.000 -0.004 0.000
-0.5 0.261 0.266 0.274 -0.015 -0.012 -0.015
-1 0.345 0.342 0.376 -0.030 -0.033 -0.027
-1.5 0.412 0.412 0.461 -0.005 -0.008 -0.002
-2 0.467 0.468 0.531 0.078 0.075 0.068
2 2 -0.574 -0.578 -0.571 -0.656 -0.656 -0.653
1.5 -0.359 -0.360 -0.357 -0.362 -0.361 -0.359
1 -0.122 -0.124 -0.122 -0.152 -0.153 -0.152
0.5 0.111 0.115 0.112 -0.034 -0.032 -0.036
0 0.317 0.320 0.324 0.000 0.003 0.002
-0.5 0.481 0.479 0.494 -0.022 -0.026 -0.026
-1 0.605 0.605 0.636 0.059 -0.059 -0.056
-1.5 0.698 0.701 0.747 -0.069 -0.069 -0.063
-2 0.769 0.770 0.833 -0.023 -0.024 -0.026
Biasanalytic2sps - bias computed using analytic formula derived for 2SPS method; Bias
AFT
2sps -bias com-
puted via simulation for 2SPS Weibull accelerated failure time model;BiasCox2sps-bias computed via
simulation for 2SPS Cox model; Biasanalytic2sri - bias computed using analytic formula derived for
2SRI method; BiasAFT2sri -bias computed via simulation for 2SRI Weibull accelerated failure time
model;BiasCox2sri-bias computed via simulation for 2SRI Cox model;
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Figure 2.4: Mean square error in estimating log causal hazard ratio using two stage
IV methods (X-axis is the magnitude of confounding ∆ , Y-axis is the Mean Square
Error).For 2SRI method or 2SPS method, the mean square error computed for each
of 1458 possible scenarios were grouped by the magnitude of shape parameter α
(decreasing hazard for α = 0.5, constant hazard for α = 1, and increasing hazard for
α = 2) and the magnitude of confounding ∆ (larger values represent lager confounding
effects and 0 represents no confounding).
Table 2.2: Bias in estimating causal hazard ratio parameter for prostate cancer study
Outcome Group IV2sri IV2sps
All cause mortality Total
(n=31541) 0.57(0.17-1.06) 0.59(0.19-1.09)
RCT Cohort
(n=12924) 0.96(0.18-5.81) 0.97(0.18-5.94)
Elderly Cohort
(n=14340) 0.74(0.20-1.83) 0.96(0.26-2.35)
Screen-Detected Cohort
(n=4277) 0.34(0.02-2.99) 0.35(0.03-3.22)
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CHAPTER 3
A GENERAL FRAMEWORK FOR ASSESSING BIAS IN TWO-STAGE INSTRUMENTAL
VARIABLE MODELS
3.1. Introduction
The presence of unmeasured confounding may pose challenges when clinical and health service
researchers attempt to estimate the causal effect of an exposure on study outcomes using obser-
vational data. This causal effect is often represented by a parameter associated with the exposure
variable in a structural model including outcome Y , exposure D, observed covariates X, unob-
served covariates U. The conditional causal parameter can be interpreted as the change in an
outcome per unit change in the exposure variable while keeping all other measured or unmeasured
covariates constant. When U is omitted from the model, the resulting estimator is generally bi-
ased and inconsistent in estimating the true causal parameter, even when observed covariates X
are controlled for. In epidemiology this bias is termed "confounding bias" and it is referred to as
"endogeneity" in economics.
Instrumental variables (IVs) are routinely used to account for the unmeasured confounding bias in
observational studies. A valid IV must correlate with exposure, and all the effect of IV on outcome
must be mediated via exposure (known as “exclusion restriction”). IV methods are well developed
in the context of continuous outcomes and linear models. The two stage predictor substitution
(2SPS) method, generally known as two stage least squares (2SLS) for continuous outcomes, is
one of the most widely used approaches. The fitted value from the first stage linear regression
of the exposure on the IV is used to replace the exposure in the second stage linear outcome
model. The 2SPS estimator consistently estimates the causal effect of the exposure given observed
and unobserved covariates. Two stage residual inclusion (2SRI) method is an equally popular
alternative. It includes the residual from the first stage regression as an additional covariate, in
conjunction with the exposure, in the second stage regression model. The resulting 2SRI estimator
is also a consistent estimator of conditional causal parameter. However, clinical and health service
researchers are often interested in evaluating discrete or time to event data. The extensions of the
two stage IV approaches to generalized linear models and survival models have been proposed in
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a straightforward approach (Terza, Basu, and Rathouz, 2008). In correspondence with each type
of outcome, the second stage linear model is simply replaced with the corresponding nonlinear
models (i.e, Logistic, Poisson, and Cox proportional hazard models).
However, the consistency of the two stage IV estimators in the context of nonlinear models remains
unclear. Terza, Basu, and Rathouz, 2008 constructed a two stage nonlinear modeling framework to
account for endogeneity. Within this framework the 2SRI method consistently estimates the causal
effect of endogenous exposure variables but the 2SPS estimator is biased and inconsistent. Be-
cause of these findings, the 2SRI approach has been advocated as the method of choice in clinical
studies involving discrete and survival outcomes (Gore et al., 2010; Hadley et al., 2010; Mortensen
et al., 2014; Tan et al., 2012). Wang, 2012 investigated the relationship between pharmacokinetics,
a measure of drug exposure, and the risk of adverse events with Poisson regression models and
dose level as the IV. The author demonstrated the consistency of the 2SPS and 2SRI estimators
analytically and with simulation. IV methods have become increasingly popular in epidemiological
literature with Mendalian randomization as well. However, both the 2SRI and 2SPS approaches
have been demonstrated to be biased in estimating phenotype-disease log odds ratio, in which
dichotomous gene is IV and the exposure is a continuous phenotype (Burgess, 2013; Palmer et al.,
2008). Such biases increase with the increasing magnitude of unmeasured confounding.
Confounding also occurs in randomized trials when patients fail to comply with the treatment as-
signment. The reasons for their compliance with treatment or not may impact the outcome as
well. For example, patients with poor prognosis may have worse outcome and they may be more
(or less) compliant than patients with good prognosis. Nagelkerke et al., 2000 proposed a 2SRI
type estimator for treatment effects in a two-arm randomized trial with non-compliance for nonlinear
models. The residual is first estimated from a regression model of the actual treatment received
on treatment assignment indicator. Treatment assignment is a perfect IV because it satisfies the
core assumptions of IV (Baiocchi, Cheng, and Small, 2014). The estimated residual and treatment
indicator are included in the second stage nonlinear model to estimate treatment effects. However,
the bias of this 2SRI estimator increases with increasing confounding (Ten Have, Joffe, and Cary,
2003). When treatment effect is heterogeneous and under certain assumptions, Angrist, Imbens,
and Rubin, 1996 proved that the 2SLS estimator converges to the local average treatment effect
(LATE) among compliers within potential outcomes and principal stratification framework. Complier
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is a sub-population of patients that always comply with the treatment assigned. For binary outcome
and time to event outcome, Cai, Small, and Ten Have, 2011 and Wan et al., 2015 showed ana-
lytically and via simulation that both the 2SPS and 2SRI methods are biased in estimating causal
odds ratios and causal hazard ratios among compliers, respectively.
In light of the increasing interests in applying 2SPS and 2SRI methods in clinical and health service
research for discrete or time to event data and conflicting conclusions in the current literature, the
purpose of this paper is to investigate the consistency of the 2SPS and 2SRI estimators in three
commonly used nonlinear models. We propose a new two stage modeling framework that is more
relevant to clinical settings. Under this framework, we demonstrate that the bias in 2SPS and 2SRI
estimators can be transformed into the problem of omitted variables in non-linear models. We then
perform comprehensive simulation to assess the bias of 2SPS and 2SRI. Finally, we analyze infant
birth defect data using the 2SPS and 2SRI.
3.2. Notations, Assumptions, and Framework
3.2.1. The nonlinear model framework in current literature
The causal relationship between endogenous variables and discrete or time-to-event outcome vari-
ables is often formulated within structural equation modeling frameworkTerza, Basu, and Rathouz,
2008. Such models are widely used in economics. Conditional on observed exogenous variables
and unobserved confounding variables, the true nonlinear model that explain the causal effects of
covariates on the outcome variable Y is assumed to have the following functional form
Y = f(βTeXe + β
T
oXo + β
T
uXu) + e, E(e|Xe,Xo,Xu) = 0. (3.1)
where f(·) is a known nonlinear function, Xe =< xe1 , xe2 , ..., xep > is a p−vector of endogenous ex-
posure variables and βe =< βe1 , βe2 , ..., βep > is a p−vector of parameters of interest measuring the
causal effects of exposure variables Xe on outcome Y conditional on observed and unobserved co-
variates, Xo =< xo1 , xo2 , ..., xok > is a k−vector of observed covariates, Xu =< xu1 , xu2 , ..., xup >
is a p−vector of unobserved covariates that are correlated with endogenous variables Xe. βo and
βu are k−vector and p−vector of regression parameters for Xo and Xu, respectively. e is a random
error that is not correlated with {Xe,Xo,Xu}.
51
Simply fitting a regression model of Y on observed variables Xe and Xo may result in a biased
estimate of βe because of endogeneity. To formalize the relationship between Xe and Xu and to
reveal how IV can be used to correct endogeneity bias, the following set of nonlinear auxiliary (or
reduced form) equations are defined for each pair of an endogenous exposure variable and an
unmeasured covariate:
xes = gs(α
T
0Xo + α
T
1R) + xus for s = 1, 2, 3, ..., p (3.2)
where g(·) is a known nonlinear function, R =< r1, r2, ..., rm > is a m−vector of IVs and α1 =<
α1,1, α1,2, ..., α1,m > is a m−vector coefficient vector(m ≥ p). Under the nonlinear model frame-
work specified by equations (3.1) and (3.2), Terza, Basu, and Rathouz, 2008 concluded that 2SRI
produces consistent estimates of conditional causal parameters βe for nonlinear outcome models.
In clinically relevant settings, however, only one endogenous exposure variable but multiple un-
measured covariates are often involved. The modeling framework defined by equations (3.1) and
(3.2) requires an inherent assumption that the effects of unmeasured covariates on the outcome
variable are proportional to their effects on the endogenous exposure variable. Only under this
strict assumption the consistency of the 2SRI estimator can be established. In the next section, we
propose a new framework to assess the bias of two stage IV models in estimating the conditional
treatment effect of an exposure variable when such an assumption is violated.
3.2.2. A new nonlinear model framework for assessing bias
In this new framework, we let D represent a continuous exposure variable, X =< x1, x2, ..., xk >
be a k−vector of observable covariates, and U =< u1, u2, ..., up > represent a p−vector of unob-
servable covariates that may be correlated with D. For simplicity and without loss of generality,
we assume both X and U are all standardized with zero mean and one unit standard deviation.
Let η(·) denote the linear predictor in a regression model including exposure variable D, measured
covariates X, and unmeasured covariates U, and is written as
η = β0 + β1D + β
T
2 X + β
T
3 U︸ ︷︷ ︸
ε1
(3.3)
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β1 is the parameter of interest and represents the treatment effect of exposure variable D on the
outcome, conditional on measured covariates X and unmeasured covariates U. We assume that
there is no interaction between the treatment effect and the level of measured and unmeasured
covariates. β2 and β3 are k−vector and p−vector of regression coefficients for X and U, respec-
tively. In particular, We define β3 = kb3, where k is a constant and b3 =< b3,1, b3,2, ..., b3,p >
is a p−dimensional normalized unit vector such that ‖b3‖ = 1. It should be noted that k 6= 0
and thus β3 6= 0 because some of unmeasured covariates must be correlated with outcome,
otherwise model (3.3) has no endogeneity problem, and conditional treatment effect, measured
by "β1", can be estimated consistently by controlling for observed covariates X. We also define
ε1 = β
T
3 U = k
∑m
i=1 b3,iui as an implicit error term for model (3.3).
When outcome Y is binary or count, the nonlinear outcome model (3.1) becomes
G(E(Y |D,X,U)) = η(D,X,U)
where G(·) is a known link function, e.g., logit link for binary data and log link for count data.
When outcome Y is time to event, the nonlinear outcome model (1) can be represented by a log
hazard function
log{λ(Y = t|D,X,U)} = η(D,X,U)
where λ is hazard function. In this case, β0 in equation (3.3) becomes β0(t) = log(λ0(t)), the log
baseline hazard function.
Suppose we have an IV R, the linear treatment model in the form of equation (3.2) is formulated as
D = α0 + α1R+ α
T
2 X + α
T
3 U︸ ︷︷ ︸
ε0
(3.4)
where α2 and α3 are k−vector and p−vector of coefficients for X and U, respectively. We then
define α3 = la3, where l is a constant and a3 =< a3,1, a3,2, ..., a3,p > is a p−normalized vector
such that ‖a3‖ = 1, and the implicit error ε0 = αT3 U = k
∑m
i=1 a3,iui. The treatment model (3.4)
is a standard specification for a continuous endogenous variable in the two stage IV modeling
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framework. It should be emphasized that IV R is assumed to be a univariate variable throughout
the paper only for simplicity reason but this assumption can be relaxed to accommodate multiple
IVs.
The two stage nonlinear modeling framework defined by equations (3.3) and (3.4) possesses the
following properties: (P.1) If b3,i = 0 and a3,i 6= 0 for some i ∈ {1, 2, ..., p}, then unobserved variable
ui is an independent predictor or measurement error of the treatment model (3.4). That is, ui
impacts D but not Y ; (P.2) If b3,i 6= 0 and a3,i = 0 for some i ∈ {1, 2, ..., p}, then unobserved variable
ui is an independent predictor or measurement error of the outcome model (3.3). ui impacts Y
but not D; (P.3) If b3,i 6= 0 and a3,i 6= 0 for some i ∈ {1, 2, ..., p}, then unobserved variable ui is a
confounder of the association between outcome Y and treatment D.
Within this two stage modeling framework, we require the following standard IV assumptions: (C.1)
R ⊥ U|X, IV R is independent of U conditional on X ; (C.2) R correlates with D sufficiently
conditional on {X,U}. That is, R is a strong IV ; (C.3) E(U|X) = E(U) = 0, unmeasured covariates
U is mean independent of observed covariates X.
Under (C.1), we can infer that any linear combination of unmeasured covariates U is independent
of R conditional on measured covariates X so that βT3 U ⊥ R|X in model (3.3) and αT3 U ⊥ R|X
in model (3.4). Thus, we have cov(ε1, R) = 0 and cov(ε0, R) = 0, two classic assumptions for IV
R under a structural model framework. The conditional independence of IV R and error term ε1
ensures the exclusion restriction assumption is satisfied. That is, there is no direct effect of IV R on
the outcome and all of its effect on the outcome has to go through exposure D. Assumption (C.2)
assures that there is a strong correlation between IV R and exposure D and thus the possibility
of the bias from a weak IV is excluded. The mean independence assumption specified in (C.3)
suggests that observed covariates X are exogenous in models (3.3) and (3.4) because we have
E(βT3U|X) = 0 and E(αT3U|X) = 0. In next section, we demonstrate that under this new framework,
the 2SPS and 2SRI estimators are consistent when outcome is continuous but such consistency
does not necessarily hold for nonlinear models, even with a valid IV.
54
3.3. Bias analysis
In this section, we utilize the two stage modeling framework proposed in section (3.2.2) to assess
the potential bias in estimating "conditional" treatment effect, represented by β1 in model (3.3),
using the 2SPS and 2SRI approaches. We first transform bias problems for 2SPS and 2SRI in
nonlinear models into bias problems of omitting variables in nonlinear models in section(3.3.1) and
section(3.3.2). We investigate the relationship between omitted terms of 2SPS and 2SRI in section
(3.3.3). Next, in section(3.3.4) we specifically evaluate the performance of 2SPS and 2SRI in
Poisson, Logistic, and Cox proportional hazard models. In section(3.3.5) two metrics are proposed
to quantify the relationship between unmeasured covariates and the magnitude of bias for 2SPS
and 2SRI, respectively.
3.3.1. Two stage predictor substitution method
First substitute the exposure variable D defined by equation (3.4) into equation (3.3)
η = β0 + β1(α0 + α1R+ α
T
2X + α
T
3U) + β
T
2X + β
T
3U
= β0 + β1(α0 + α1R+ α
T
2X) + β
T
2X + ε (3.5)
where the implicit error ε = (β1αT3 + βT3 )U.
Under assumptions (C.1) and (C.3), taking the expectation of both sides of model (3.4) conditional
on R and X gives
E(D|R,X) = α0 + α1R+ αT2X
Then equation (5) becomes
η = β0 + β1E(D|R,X) + βT2X + ε (3.6)
In equation (3.6), E(D|R,X) is a function of IV R and X, and ε is a linear combination of unmea-
sured covariates U. Thus, E(D|R,X) ⊥ ε|X by assumption (C.1).
2SPS first estimates the predicted value of D using a linear regression model including R and X
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only,
D̂ = α̂0 + α̂1R+ α̂
T
2X
This D̂ consistently estimate E(D|R,X) because OLS estimators {α̂0, α̂1, α̂2} are unbiased and
consistent. Therefore, in the scenario where the outcome Y is continuous, equation (3.6) can be
approximated asymptotically by
Y = β∗0 + β
∗
1D̂ + β
∗T
2 X + ε
As n→∞, D̂ p→ E(D|R,X), and β∗1
p→ β1. Conditional on X, D̂ is independent of ε asymptotically.
The 2SPS estimator β̂∗1
p→ β∗1 , and so β̂∗1
p→ β1. Therefore, 2SPS consistently estimates the causal
parameter β1 when outcome is continuous.
However, when outcome is not continuous and a nonlinear outcome model needs to be fitted in
the second stage, the consistency of the 2SPS estimator may fail. For example, when Y is binary
or time to event outcome, the second stage outcome model of the 2SPS method, according to
equation (3.6), can be written as,
G(E(Y |R,X,U)) = β0 + β1E(D|R,X) + βT2X + ε (3.7)
where G(·) is logit link function, or
log{λ(Y = t|R,X,U)} = β0(t) + β1E(D|R,X) + βT2X + ε (3.8)
where λ(·) is the hazard function and β0(t) = log(λ0(t)) is the baseline log hazard function. But
since unmeasured confounders U are not observed and ε is omitted from models (3.7) and (3.8),
one is forced to fit a reduced model
G(E(Y |R,X)) = β̃0 + β̃1E(D|R,X) + β̃T2X (3.9)
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for generalized linear models,or
log{λ(Y = t|R,X)} = β̃0(t) + β̃1E(D|R,X) + β̃T2X (3.10)
for hazard models. This reduced model can be interpreted as a marginal model with respect to
omitted error term ε. The "marginal" causal parameter β̃1 in models (3.9) and (3.10) may differ
from the "conditional" parameter β1 in models (3.7) and (3.8) (Gail, Wieand, and Piantadosi, 1984;
Zeger, Liang, and Albert, 1988). This phenomenon is also known as noncollapsibility. Thus, when
predicted values D̂ replaces E(D|R,X) in models (3.9) and (3.10), the corresponding models be-
come
G(E(Y |R,X)) = β̃∗0 + β̃∗1D̂ + β̃∗T2 X (3.11)
or,
log{λ(Y = t|R,X)} = β̃∗0(t) + β̃∗1D̂ + β̃∗T2 X (3.12)
As n→∞, the 2SPS estimator ̂̃β∗1 consistently estimate β̃∗1 . Also, When D̂ p→ D, β̃∗1 p→ β̃1, and then̂̃
β∗1
p→ β̃1. However, the 2SPS estimator ̂̃β∗1 may fail to estimate the conditional causal parameter β1
consistently because the marginal parameter β̃1 could differ from β1 depending on the collapsibility
of the outcome models.
3.3.2. Two stage residual inclusion method
Similarly, under the same two stage framework defined by equations (3.3) and (3.4), the 2SRI
estimator could be biased as well. First, we decompose β3, coefficient vector for unmeasured
covariates in equation (3.3), into two orthogonal components: one along with the direction of α3,
coefficient vector of unmeasured covariates in treatment model (3.4), and the other vector orthog-
onal to α3 (Figure 2.1),
β3 =
‖β3‖
‖α3‖
cos(θ)α3 + (β3 −
‖β3‖
‖α3‖
cos(θ)α3)
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Re-express βT3U term in equation (3.3) as
βT3U =
‖β3‖
‖α3‖
cos(θ)αT3U + (β
T
3 −
‖β3‖
‖α3‖
cos(θ)αT3)U (3.13)
Equation (3.13) can be interpreted as a least square projection of βT3U onto αT3U.
‖β3‖
‖α3‖cos(θ) is the
regression coefficient. The second term is the residual (details see Appendix A). It is noteworthy
that βT3 − ‖β3‖‖α3‖cos(θ)α
T
3 = β
T
3sin(θ).
Substituting equation (3.13) into equation (3.3), we get
η = β0 + β1D + β
T
2X +
‖β3‖
‖α3‖
cos(θ)αT3U + (β
T
3 −
‖β3‖
‖α3‖
cos(θ)αT3)U (3.14)
A simple manipulation of equation (3.4) leads to,
αT3U = D − (α0 + α1R+ αT2X) = D − E(D|R,X)
which can be interpreted as a "residual" term from the first stage linear treatment model. Therefore,
Equation (3.14) can be written as,
η = β0 + β1D + β
T
2X + γ1δ + ν (3.15)
where
δ = D − E(D|R,X)
γ1 =
‖β3‖
‖α3‖
cos(θ)
ν = (βT3 −
‖β3‖
‖α3‖
cos(θ)αT3)U
In equation (3.15), D is a function of R, X, and αT3U, and the implicit error ν is a linear combination
of unmeasured confounders U. Given the fact that δ = αT3U, it is easy to show D ⊥ ν|{X, δ} by
condition (C.1). Exposure D is exogenous in model (3.15) once observed covariates X and the
residual δ from treatment model are controlled for.
The 2SRI approach first estimates the residual δ using a linear regression model including R and
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X only,
δ̂ = D − D̂ = D − (α̂0 + α̂1R+ α̂T2X)
This δ̂ consistently estimate δ because of consistency of OLS estimators {α̂0, α̂1, α̂2}. When the
outcome Y is continuous, equation (3.15) can be approximated asymptotically by
Y = β∗0 + β
∗
1D + β
∗
2X + γ
∗
1 δ̂ + ν (3.16)
As n → ∞, δ̂ p→ δ, and β∗1
p→ β1. Conditional on X and δ̂, the exposure variable D is independent
of ν asymptotically in model (3.16). Thus, β̂∗1
p→ β∗1 , and β̂∗1
p→ β1 . Therefore, the 2SRI estimator
β̂∗1 consistently estimate the parameter of interest β1 when the outcome model is a linear model.
However, like the 2SPS estimator, when the outcome is not continuous and a nonlinear outcome
model is fitted in the second stage, the consistency of the 2SRI estimator is also questionable. For
example, when Y is binary or time to event outcome, the second stage outcome model of 2SRI
approach, according to equation (3.15), can be written as,
G(E(Y |D,R,X,U)) = β0 + β1D + β2X + γ1δ + ν (3.17)
where G(·) is logit link function, or
log{λ(Y = t|D,R,X,U)} = β0(t) + β1D + β2X + γ1δ + ν (3.18)
where λ(·) is the hazard function and β0(t) = log(λ0(t)) is the baseline log hazard function. But
since unmeasured confounders U are not observed and ν term is omitted from models (3.17) and
(3.18),the resulting "marginal" models are
G(E(Y |D,R,X)) = β̃0 + β̃1D + β̃2X + γ̃1δ (3.19)
, or
log{λ(Y = t|D,R,X)} = β̃0(t) + β̃1D + β̃2X + γ̃1δ (3.20)
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The marginal causal parameter of β̃1 in models (3.19) and (3.20) may differ from β1 in models
(3.17) and (3.18) (Gail, Wieand, and Piantadosi, 1984; Zeger, Liang, and Albert, 1988). When the
estimated residual δ̂ replaces δ in models (3.19) and (3.20), the corresponding models are
G(E(Y |D,R,X)) = β̃∗0 + β̃∗1D + β̃∗2X + γ̃∗1 δ̂ (3.21)
, or
log{λ(Y = t|D,R,X)} = β̃∗0 + β̃∗1D + β̃∗2X + γ̃∗1 δ̂ (3.22)
As n → ∞, δ̂ p→ δ and β̃∗1
p→ β̃1. The 2SRI estimator ̂̃β∗1 consistently estimate β̃∗1 , and β̃1, but ̂̃β∗1
may not be a consistent estimator of β1 because β̃1 could be different from β1.
3.3.3. Relationship between omitted terms in 2SPS and 2SRI
As discussed in sections (3.3.1) and (3.3.2), the omitted error term ε of 2SPS is (β1αT3 + βT3 )U and
the omitted error term ν of 2SRI is (βT3 − ‖β3‖‖α3‖cos(θ)α
T
3)U. The norm of the coefficient for ε has the
following relationship with the norm of the coefficient for ν
‖β1αT3 + βT3‖2 = ‖βT3 −
‖β3‖
‖α3‖
cos(θ)αT3‖2 + ‖(β1 +
‖β3‖
‖α3‖
cos(θ))αT3‖2
Then, we have
‖β1αT3 + βT3‖ ≥ ‖βT3 −
‖β3‖
‖α3‖
cos(θ)αT3‖
The details are in Appendix A.
3.3.4. Two stage Poisson,Logistic,and Survival IV Models
As revealed in section (3.3.1) and (3.3.2), 2SPS decomposes the endogenous exposure variable
D into two components: 1) the endogenous component β1αT3U, which is integrated into the error
term; 2) the exogenous component E(D|R,X), which is exogenous to the error term. On the other
hand, 2SRI decomposes the unmeasured component βT3U into two orthogonal components: 1)
the estimable component αT3U, which is the residual from the first stage treatment model; 2) the
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composite error term ν. Controlling for the estimable component, IV, and observed covariates, the
exposure variable is exogenous to this error term. Thus, omitting these endogenous error terms
does not cause any bias in estimating the conditional causal parameter when we apply 2SPS or
2SRI to linear models. However, a "marginal" model, resulting from omitting composite error terms,
may have different parameters from the corresponding the "conditional" model for nonlinear models
(Zeger, Liang, and Albert, 1988). The term "bias" for two stage IV methods is defined as β1 − β̃1,
the difference between conditional causal parameter β1 and marginal causal parameter β̃1 to which
two stage IV estimators converges to when composite error term ε or ν is ignored. Next, we use
approaches adopted by Lin, Psaty, and Kronmal, 1998 and Mitra and Heitjan, 2007 to examine the
bias of 2SPS and 2SRI in Poisson, logistic, and Cox proportional hazard models.
(1) Poisson model: Suppose that Y is a response variable taking integer values 0, 1, 2, ...N and
Y |{D,X,U} ∼ Pois(eη), where η is the linear predictor defined by equation (3.3). The
marginal form of 2SPS Poisson model is
E(Y |R,X) = exp(β0 + β1E(D|R,X) + βT2X)c(X)
where c(X) =
∫∞
−∞ exp(ε)dF (ε|X), a function of X only (details in Appendix B). Both the
marginal Poisson model and conditional Poisson model have the same parameter β1.
The marginal model of 2SRI Poisson model is
E(Y |D,R,X) = exp(β0 + β1D + βT2X + γ1δ)c(X, δ)
where c(X, δ) =
∫∞
−∞ exp(ν)dF (ν|X, δ). It is a function of X and δ. The marginal model and
conditional model have the same causal parameter β1 associated with exposure D (details in
Appendix B). Therefore, both 2SPS and 2SRI Poisson models yield consistent estimates of
conditional treatment effect.
(2) Logistic outcome model. Now assume Y is a response variable taking binary values of 0 or 1,
and Y |{D,X,U} ∼ Bernoulli( eη1+eη ), where η(·) is linear predictor defined by equation (3.3).
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The marginal form of 2SRI logistic model is
logit{P(Y = 1|D,R,X)} = β0 + β1D + β2X + γ1δ + g(D,R,X)
where
g(D,R,X) = log
A
B
and,
A =
∫ ∞
−∞
exp(ν)
1 + exp(β0 + β1D + β2X + γ1δ) + ν)
dF (ν|δ,X)
B =
∫ ∞
−∞
1
1 + exp(β0 + β1D + β2X + γ1δ) + ν)
dF (ν|δ,X)
The marginal form of the 2SPS logit outcome model (3.7) is
logit{P(Y = 1|D,R,X)} = β0 + β1E(D|R,X) + β2X + g(R,X)
The derived bias term g(R,X) for 2SPS logistic model is
g(R,X) = log
A
B
where
A =
∫ ∞
−∞
exp(ε)
1 + exp(β0 + β1E(D|R,X) + β2X + ε)
dF (ε|X)
B =
∫ ∞
−∞
1
1 + exp(β0 + β1E(D|R,X) + β2X + ε)
dF (ε|X)
When there is no treatment effect (β1 = 0), both 2SRI and 2SPS are consistent. When the
treatment effect is not null but coefficients for implicit error terms (ν or ε ) are zero, both 2SRI
and 2SPS are also consistent. That is, β1αT3 + βT3 = 0 for 2SPS and βT3 − ‖β3‖‖α3‖cos(θ)α
T
3 = 0
for 2SRI (details in Appendix C). A simple form of the relationship between marginal and
conditional causal parameters can be approximated by the following expressions if we can
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assume that R ⊥ U without conditional on X Zeger, Liang, and Albert, 1988,
β̃1 ≈
β1√
1 + c2‖βT3 − ‖β3‖‖α3‖cos(θ)α
T
3‖2
for 2SRI, and
β̃1 ≈
β1√
1 + c2‖β1αT3 + βT3‖2
for 2SPS, where c = 16
√
3/(15π). As the magnitudes of the effects of omitted error terms,
measured by ‖βT3 − ‖β3‖‖α3‖cos(θ)α
T
3‖ or ‖β1αT3 + βT3‖ for 2SRI or 2SPS respectively, increases,
the values of marginal parameters β̃1 shrink towards the null effect. The bias β̃1 − β1 is a
function of treatment effect β1.
(3) Cox proportional hazard model. Let Y be the time to event. Given exposure D, measured
covariates X and unmeasured covariates U, the marginal form of 2SRI Cox proportional
hazard model (3.20) can be written as
λ(t|D, δ,X) = λ0(t)exp(β1D + β2X + γ1δ)g(t,D,R,X)
where bias term
g(t,D,R,X) =
∫∞
−∞ exp(ν)(exp(−Λ0(t)exp(β1D + β2X + γ1δ + ν)dF (ν|R,X)∫∞
−∞ exp(−Λ0(t)exp(β1D + β2X + γ1δ + ν)dF (ν|R,X)
and the marginal form of 2SPS Cox proportional hazard model (3.8) can be written as
λ(t|R,X) = λ0(t)exp(β1E(D|R,X) + β2X)g(t, R,X)
where bias term
g(t, R,X) =
∫∞
−∞ exp(ε)(exp(−Λ0(t)exp(β1E(D|R,X) + β2X + ε)dF (ε|R,X)∫∞
−∞ exp(−Λ0(t)exp(β1E(D|R,X) + β2X + ε)dF (ε|R,X)
When there is no treatment effect (β1 = 0), both 2SRI and 2SPS are consistent. When the
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treatment effect is not null but coefficients for implicit error terms (ν or ε ) are zero, both 2SRI
and 2SPS are consistent (details in Appendix D).
It is difficult to derive a simple closed form expression of β̃1 in terms of β1 for Cox model with
censoring. If we assume there is no observed covariate and by the results of Lin, Logan, and
Henley, 2013, β̃1 is the solution to the following score equation:
0 = S(β̃1, β1, φ)
= Eobs
[
D − EDU
{
eβ̃1De−H0(t)e
β1D+φU
DC(t)
}
EDU
{
eβ̃1De−H0(t)e
β1D+φUC(t)
} ]
where φ = β1αT3 + βT3 for 2SPS or φ = βT3 − ‖β3‖‖α3‖cos(θ)α
T
3 for 2SRI. C(t) is censoring distri-
bution. Eobs is the mean over subjects with events. EDU is the expectation with respect to
exposure variable D and unmeasured covariates U.
3.3.5. Dissimilarity metric
The magnitude of coefficients for omitted terms is one important factor influencing the bias (Neuhaus
and Jewell, 1993). ‖β1αT3 + β3‖ is the size of coefficient for 2SPS. For 2SRI, the coefficient vector
βT3 − ‖β3‖‖α3‖cos(θ)α
T
3 is equal to βT3sin(θ). The metric ‖βT3‖sin(θ) reveals two sources of biases for
2SRI: the magnitude of effects of unmeasured covariates on outcome, represented by ‖βT3‖, and
the "dissimilarity" between coefficient vectors α3 and β3, measured by sin(θ). The sin(·) function
measures the dissimilarity between two coefficient vectors and it satisfies the three criteria for a
standard distance measure: i) non-negativity and identity of indiscernibles; ii) symmetry; iii) triangle
inequality (Details see Appendix A). Larger values of this metric suggests two vectors are more
dissimilar.
3.4. Simulation
3.4.1. Simulation algorithm
As discussed in previous sections, various factors may impact the bias in estimating conditional
treatment effect when applying 2SPS and 2SRI in nonlinear models, such as size of treatment
effect, magnitude of unmeasured confounding, dissimilarity between the two coefficient vectors of
unmeasured covariates, and censoring proportion etc. We design a comprehensive simulation
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study, according to the following steps, to assess the impact of these factors:
(I) We set the size of treatment effect at three levels: β1 = {0, 0.4, 0.8}.
(II) IV R ∼ N(0, 1), each of four unmeasured variables ui ∼ N(0, 1) for i ∈ {1, 2, 3, 4}. In treat-
ment model (3.4), the coefficients for IV and unmeasured covariates are determined in such
way that the desired strong association between IV and treatment variable are achieved. We
use the explained proportion of variation, R2 = var(α1R)/var(α1R+
∑4
i=1 α3,iui), to measure
the strength of IV because this measure is not variable with changing sample size. We let
α0 = 1.2 and α1 = 2. The coefficient vector for unmeasured variables is α3 = l × a3, where
a3 = {a3,1, a3,2, a3,3, a3,4} is a unit vector. The explained proportion of variation by IV R is
4/(4 + 1 ∗ l2). We fix l = 1, R2 attributable to IV is ∼ 80%. In outcome model (3.3), coeffi-
cient vector for unmeasured covariates is β3 = k × b3, where b3 = {b3,1, b3,2, b3,3, b3,4} is a
unit vector and k is chosen to be 0.5, 1, or 2, representing low, medium, and high levels of
effects of unmeasured covariates on outcome. Each element in vectors a3 and b3 are sam-
pled randomly from {0, 1, . . . , 8, 9} first and then normalized. The signs of each coefficient are
generated randomly from ∼ Bernoulli(p = 0.5).
(III) For each pair of coefficient vectors α3 and β3, we simulated a sample of 10000 observations
for each type of outcomes (binary, count, and time to event) using equations (3.3) and (3.4).
Specifically, count data are generated using Poisson distribution ∼ P (µ = exp(η)), where η is
the linear predictor defined in equation (3.3). Binary data are generated from∼ Bernoulli(p =
exp(η)
1+exp(η) ). Time to event data are simulated using ∼ Weibull(α,exp(η)). Censoring time is
also generated using∼Weibull(α, c). Shape parameter α are set at {0.5, 1, 1.5}, representing
decreasing, constant, and increasing hazard scenarios. Value of scale parameter c is chosen
to yield 0%, 45%, and 65% censoring rate.
(IV) For each combination of influencing factors, we generate 2000 pairs of coefficient vectors. For
each pair, we simulate a data with 10000 observations. We use the 2SRI and 2SPS methods
to estimate conditional treatment effect β1 on each simulated data. The process is repeated
for 1000 times and these 1000 estimates of treatment effect are averaged to compute the
2SRI and 2SPS estimators.
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3.4.2. Simulation results
Under the null hypothesis of no treatment effect, 2SRI estimators are unbiased in all scenarios
for Poisson, logistic and Cox proportional hazard models (Supplementary Figure 3.7,3.8, and 3.9).
When treatment effect is not null, the results are mixed. For Poisson models, 2SRI produces con-
sistent estimates of the conditional treatment effect for most scenarios. When two vectors are highly
dissimilar and unmeasured effects are high, there are some minor bias(Figure 3.2). For logit mod-
els, the bias of 2SRI tends to increase as treatment effect size and dissimilarity metric increases.
The magnitude of the increasing trend is magnified by the strength of effect of unmeasured co-
variate on outcome. Stronger unmeasured effect, which ranges from 0.5 to 1.5, larger increase in
bias of 2SRI (Figure 3.3). Figures 3.4 and 3.4 reveals the results for Cox model. The bias of 2SRI
increases with increasing dissimilarity. Higher unmeasured effect, larger bias (Figure 3.4). Larger
size of treatment effect, larger bias (Figure 3.5). Bias of 2SRI is the highest with increasing hazard
function. Censoring provides some protective effect. 2SRI in Censored data is less biased than in
non-censored data. 2SPS exibits similar trends with its norm ‖β1α3 + β3‖ (Data not shown). 2SRI
estimators are less biased and have more variability than 2SPS estimators (Figure 3.6).
3.5. Discussion
Because of their simplicity, two stage IV methods are very popular approaches to control for un-
measured confounding among health service researchers. The conclusions from previous studies
are in conflicts (Burgess, 2013; Cai, Small, and Ten Have, 2011; Palmer et al., 2008; Wan et al.,
2015). To comprehensively evaluate the consistency of 2SPS and 2SRI in nonlinear models, We
proposed a new two stage modeling framework which accommodates clinical settings that often
involve single exposure variable and multiple unmeasured covariates. Within this framework, we
demonstrate that bias problems of 2SRI and 2SPS can be reduced to the extensively studied bias
problems from omitting variables in non-linear models (Gail, Wieand, and Piantadosi, 1984; Lin,
Psaty, and Kronmal, 1998). Instead of estimating the conditional causal parameter, the two stage
IV estimators converge to a marginal causal parameter when the composite error terms, consisting
of unmeasured covariates, are not accounted for. The magnitude of bias can be assessed by com-
paring the difference between conditional causal parameter and marginal one. When treatment
effect is null, both 2SPS and 2SRI are unbiased. However, when treatment effect is not null, we
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can not simply extend 2SRI or 2SPS to logistic or Cox models without producing biased estimates.
The attenuation of estimated conditional treatment effect suggests the 2SPS or 2SRI estimators
are biased towards null hypothesis based on simulation and analytic results.
We further revealed that the bias of the 2SRI estimator is also attributable to the dissimilarity be-
tween the effects of unmeasured covariates on the outcome and their effects on the treatment. The
more similar between their effects on treatment and outcome, the less biased the 2SRI estimator
is. The consistency of the 2SRI estimator is only established when the effects on the outcome and
the treatment of unmeasured covariates are proportional to each other. However, this assumption
is too strict to hold in real settings.
The framework and findings proposed in the current study may be helpful to address a wide range
problem with applications of two stage IV methods in estimating the conditional treatment effect. In
this paper, we have used this framework to explain the conflicting conclusions when applying two
stage IV methods to different types of outcomes in the current literature. This framework may also
be used as guidance to evaluate the alternative two stage regression model based IV approaches.
3.6. Appendix
Appendix A: Proofs for Coefficient Vectors
(A.1): A new dissimilarity measure between two vectors Let x and y denote the two k−element
vectors, and θ be the angle between two vectors. The sine dissimilarity, sin(θ), between two vectors
is defined by their cross product and magnitudes as
sin(θ) =
x× y
‖x‖‖y‖
This sine dissimilarity metric satisfies the three criteria for common distance measure: 1) non-
negativity and identity of indiscernibles; 2) symmetry; 3) triangle inequality. Proofs are given as
follows:
1. Non-negativity and identity of indiscernibles: Distance is positive between two different points,
and is zero precisely from a point to itself. That is, d(x,y) ≥ 0, and d(x,y) = 0 if and only if x =
y.
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Proof:
Non-negativity:
Let θ denote the angle between vectors x, y and 0 ≤ θ ≤ π
d(x, y) = sin(θ)
≥ 0 ∀ θ ∈ [0, π]
Identity of indiscernibles:
When x and y are in the same or opposite directions, y = ±x, two vectors are considered to
be similar under both situations "equivalently". That is, when the angle between two vectors
are 0 and sin(0) = 0, x and y are similar. when the angle between two vectors are π and
sin(π) = 0, x and y are similar. If x and y are similar (the angle θ between two vectors is
either 0 or π), d(x, y) = sin(θ) = 0.
2. Symmetry: the distance between x and y is the same in either direction. That is, d(x, y) =
d(y, x).
Proof:
Let θ denote the angle between vectors x, y and 0 ≤ θ ≤ π
d(x, y) = sin(θ)
= d(y, x)
3. Triangle inequality: the distance between two points is the shortest distance along any path.
That is, d(x, z) ≤ d(x, y) + d(y, z), ∀x, y, z.
Proof:
Let θ1 denote the angle between vectors x, y, θ2 denote the angle between vectors y, z, and
θ3 denote the angle between vectors x, z. 0 ≤ θi ≤ π,∀i ∈ 1, 2, 3
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(3.1) When θ3 = θ1 + θ2
θ3
θ1
θ2
x
y
z
d(x, z) = sin(θ3)
= sin(θ1 + θ2)
= sin(θ1)cos(θ2) + cos(θ1)sin(θ2)
≤ sin(θ1) + sin(θ2) = d(x, y) + d(y, z)
(3.2) When θ1 = θ3 − θ2
θ3
θ1
θ2
x
z
y
69
d(x, z) = sin(θ1)
= sin(θ3 − θ2)
= sin(θ3)cos(θ2)− cos(θ3)sin(θ2)
≤ sin(θ3) + sin(θ2) = d(x, y) + d(y, z)
(A.2): Least square projection of βT3U onto αT3U
Let β3 and α3 denote the coefficient vectors for unmeasured covariates U in outcome model (3.3)
and treatment model (3.4). Let θ denote the angle between the two vectors.
βT3U =
‖β3‖cos(θ)
‖α3‖
αT3U + (β
T
3 − ‖β3‖cos(θ)
αT3
‖α3‖
)U (A.1)
Show the equation (A.1) is a least square projection of βT3U onto αT3U.
Proof:
When unmeasured confounders U (normalized) are independent, let ρ denote the coefficient from
least square regression of βT3U on αT3U. Let Σ denote the variance and covariance matrix of U. In
this case, Σ is an identity matrix denoted as I.
ρ =
cov(βT3U, αT3U)
var(αT3U)
=
β3 · α3
‖α3‖2
∵ Σ = I
=
‖β3‖‖α3‖cos(θ)
‖α3‖2
=
‖β3‖cos(θ)
‖α3‖
When unmeasured confounders U (normalized) are not independent, equation (A.1) is a least
square projection of βT3U onto αT3U by ignoring the correlation structure.
(A.3): Proposition: ‖β1αT3 + βT3‖ ≥ ‖βT3 − ‖β3‖cos(θ) α
T
3
‖α3‖‖
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proof:
‖β1αT3 + βT3‖2 =< β1αT3 + βT3 , β1αT3 + βT3 >
=< (β1 +
‖β3‖cos(θ)
‖α3‖
)αT3 + (β
T
3 − ‖β3‖cos(θ)
αT3
‖α3‖
),
(β1 +
‖β3‖cos(θ)
‖α3‖
)αT3 + (β
T
3 − ‖β3‖cos(θ)
αT3
‖α3‖
) >
= ‖(βT3 − ‖β3‖cos(θ)
αT3
‖α3‖
)‖2 + ‖(β1 +
‖β3‖cos(θ)
‖α3‖
)αT3‖2
+ < (β1 +
‖β3‖cos(θ)
‖α3‖
)αT3, β
T
3 − ‖β3‖cos(θ)
αT3
‖α3‖
>
+ < βT3 − ‖β3‖cos(θ)
αT3
‖α3‖
, (β1 +
‖β3‖cos(θ)
‖α3‖
)αT3 >
= ‖βT3 − ‖β3‖cos(θ)
αT3
‖α3‖
‖2 + ‖(β1 +
‖β3‖cos(θ)
‖α3‖
)αT3‖2 + 0 + 0
≥ ‖βT3 − ‖β3‖cos(θ)
αT3
‖α3‖
‖2
In third step, use the fact βT3 − ‖β3‖‖α3‖cos(θ)α
T
3 is perpendicular to αT3
Q.E.D
Appendix B: Bias analysis for omitting a random term in two stage IV Poisson model
(1) Two stage predictor substitution Poisson model From equation (3.7), the conditional expecta-
tion of Y given IV R, observed covariates X, and unmeasured covariates U can be derived
as
E(Y |R,X,U) = exp(β0 + β1E(D|R,X) + βT2X + ε) (B.1)
Let F (ε|R,X) be the conditional distribution of ε given R and X. Under condition (C.1),
ε ⊥ R|X, thus F (ε|R,X) can be simplified as F (ε|X). Given this conditional model (B.1), the
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marginal model E(Y |R,X) is
E(Y |R,X) =
∫ ∞
−∞
exp(β0 + β1E(D|R,X) + βT2X + ε)dF (ε|X)
= exp(β0 + β1E(D|R,X) + βT2X)
∫ ∞
−∞
exp(ε)dF (ε|X)
= exp(β0 + β1E(D|R,X) + βT2X)c(X)
where c(X) =
∫∞
−∞ exp(ε)dF (ε|X), a function of X only. Both the marginal Poisson model
and conditional Poisson model have the same parameter β1.
(2) Two stage residual inclusion Poisson model From equation (3.5), the conditional expectation
of outcome Y given treatment D, IV R, observed covariates X, and unmeasured covariates
U is
E(Y |D,R,X,U) = exp(β0 + β1D + βT2X + γ1δ + ν) (B.2)
Let F (ν|D,X, δ) be the conditional distribution of ν given exposure D, measured confounders
X, and residual δ. Under condition (C.1), F (ν|D,X, δ) can be simplified as F (ν|X, δ) because
D ⊥ ν|{X, δ} . Given this conditional model (B.2), the marginal model E(Y |D,R,X) is
E(Y |D,R,X) =
∫ ∞
−∞
exp(β0 + β1D + βT2X + γ1δ + ν)dF (ν|X, δ)
= exp(β0 + β1D + βT2X + γ1δ)
∫ ∞
−∞
exp(ν)dF (ν|X, δ)
= exp(β0 + β1D + βT2X + γ1δ)c(X, δ)
where c(X, δ) =
∫∞
−∞ exp(ν)dF (ν|X, δ). It is a function of X and δ. The marginal model and
conditional model have the same causal parameter β1 associated with exposure D, but the
parameters for X and δ, βT2 and γ, are different between two models.
For both 2SPS and 2SRI Poisson models, if we can relax condition (C.1) and assume that R ⊥ U
without conditional on X, c(X) and c(X, δ) become constants and thus two approaches estimate
all parameters consistently.
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Appendix C: Bias analysis for omitting a random term in two stage IV logistic model
(1) Two stage residual inclusion: In section (3.3.2), the second stage logistic model of binary
outcome Y conditional on treatment D, instrumental variable R, observed covariates X,and
unmeasured covariates U is
logit{P(Y = 1|D,R,X,U)} = β0 + β1D + β2X + γ1δ + ν (C.1)
where
δ = D − E(D|R,X)
γ1 =
‖β3‖cos(θ)
‖α3‖
ν = (βT3 − ‖β3‖cos(θ)
αT3
‖α3‖
)U
Given this logistic model (C.1), the conditional probability of Y given X, R,D is
P(Y = 1|D,R,X) = exp(β0 + β1D + β2X + γ1δ)×∫ ∞
−∞
exp(ν)
1 + exp(β0 + β1D + β2X + γ1δ + ν)
dF (ν|D, δ,X) (C.2)
where F (ν|D, δ,X) is the conditional distribution of ν given D, δ, and X. Under condition
(C.1), F (ν|D, δ,X) can be simplified as F (ν|δ,X) because D ⊥ ν|{δ,X}. When ν term is
omitted from model (C.1), model (C.1) usually does not reduce to a logistic model as follows
logit{P(Y = 1|D,R,X)} = β∗0 + β∗1D + β∗2X + γ∗1δ (C.3)
However, it is still of practical importance to investigate how well model (C.3) may approximate
model (C.2). Use the same approach by (Lin et al, 1998), we can show that the model (C.2)
is
logit{P(Y = 1|D,R,X)} = β0 + β1D + β2X + γ1δ + g(D,R,X) (C.4)
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where
g(D,R,X) = log
A
B
(C.5)
and,
A =
∫ ∞
−∞
exp(ν)
1 + exp(β0 + β1D + β2X + γ1δ) + ν)
dF (ν|δ,X)
B =
∫ ∞
−∞
1
1 + exp(β0 + β1D + β2X + γ1δ) + ν)
dF (ν|δ,X)
The Proof of (C.5) is given below.
Proof:
First, from equations (C.2) and (C.4), we can establish
exp(β0 + β1D + β2X + γ1δ + g(D,R,X))
1 + exp(β0 + β1D + β2X + γ1δ + g(D,R,X))
=
exp(β0 + β1D + β2X + γ1δ×∫ ∞
−∞
exp(ν)
1 + exp(β0 + β1D + β2X + γ1δ + ν)
dF (ν|δ,X)
Next, divide the common factor term on both sides,
exp(g(D,R,X))
1 + exp(β0 + β1D + β2X + γ1δ)exp(g(D,R,X))
=∫ ∞
−∞
exp(ν)
1 + exp(β0 + β1D + β2X + γ1δ + ν)
dF (ν|δ,X)
Last, re-express the above equation to derive the following expression for g(D,R,X)
g(D,R,X) = log
A
B
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where
A =
∫ ∞
−∞
exp(ν)
1 + exp(β0 + β1D + β2X + γ1δ + ν)
dF (ν|δ,X)
B =
∫ ∞
−∞
1
1 + exp(β0 + β1D + β2X + γ1δ + ν)
dF (ν|δ,X)
From equation (C.5), it is easy to verify that the 2SRI logistic model produces the consistent
estimate under two conditions.
(1) when β1 = 0, g(D,R,X) contains no D term. so when the treatment effects is null, there
is no difference between the causal parameters in the marginal and conditional models.
(2) when β3 − kcos(θ)a3 = 0, ν = 0, and we have g(D,R,X) = 0. Thus, model (C.4) with ν
term omitted has exactly the same causal parameter β1 as the model (C.1).
(2) Two stage predictor substitution. In section (3.3.1), the second stage logistic model of binary
outcome Y conditional on instrumental variable R, observed covariates X,and unmeasured
covariates U is
logit{P(Y = 1|R,X,U) = β0 + β1E(D|R,X) + β2X + ε
where ε = (β1α3 + β3)U. From condition (C.1), ε ⊥ E(D|R,X)|X.
Similarly, we can write a model form with a bias term when ε term is omitted as
logit{P(Y = 1|D,R,X)} = β0 + β1E(D|R,X) + β2X + g(R,X)
The derived bias term g(R,X) for two stage predictor substitution logistic model is
g(R,X) = log
A
B
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where
A =
∫ ∞
−∞
exp(ε)
1 + exp(β0 + β1E(D|R,X) + β2X + ε)
dF (ε|X)
B =
∫ ∞
−∞
1
1 + exp(β0 + β1E(D|R,X) + β2X + ε)
dF (ε|X)
The 2SPS logistic model produces the consistent estimate under the two conditions:
(1) when β1 = 0, g(R,X) contains no E(D|R,X) term. So when the treatment effects is null,
there is no difference between the causal parameters in the marginal and conditional
models.
(2) when β1α3 + β3 = 0, we have g(R,X) = 0.
Appendix D: Bias analysis for omitting a random term in two stage IV Cox proportional hazard
model
Let T denote the time to event. Using the results from sections (3.3.1) and (3.3.2), we can specify
the conditional hazard function of T under the second stage Cox proportional model for both 2SPS
and 2SRI methods separately. The corresponding bias of the 2SPS and 2SRI methods can be
assessed using the techniques laid out in (Lin et al, 1998).
(1) Two stage residual inclusion: Conditional on treatment D,instrumental variable R, observed
covariates X, and unmeasured covariates U, the log hazard function of T under the 2SRI
Cox proportional model is
log{λ(t|D,R,X,U)} = β0(t) + β1D + β2X + γ1δ + ν (D.1)
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where
β0(t) = log(λ0(t)) unspecified baseline log hazard function
δ = D − E(D|R,X)
γ1 =
‖β3‖cos(θ)
‖α3‖
ν = (βT3 − ‖β3‖cos(θ)
αT3
‖α3‖
)U
When covariates U are unmeasured and ν term is omitted, we assume the log hazard function
of T conditional on {D,R,X} is
log{λ(t|D,R,X)} = β∗0(t) + β∗1D + β∗2X + γ∗1δ (D.2)
where
β∗0(t) = log(λ
∗
0(t)) unspecified baseline log hazard function
To assess the potential difference between β1 and β∗1 , we first denote F (ν|D,R,X) as the con-
ditional distribution function of ν given D,R, and X. Under assumption (C.1), ν ⊥ D|{R,X}.
Thus, the distribution function can be simplified as F (ν|R,X). We let f(t|·) and S(t|·) be the
conditional density and survival functions of time to event T . Then λ(t|D,R,X) in model (D.2)
can be expressed as
λ(t|D,R,X) = f(t|D,R,X)
S(t|D,R,X)
=
∫∞
−∞ f(t|D,R,X, ν)dF (ν|R,X)∫∞
−∞ S(t|D,R,X, ν)dF (ν|R,X)
(D.3)
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Given model (D.1),
∫ ∞
−∞
f(t|D,R,X, ν)dF (ν|D,R,X) =
∫ ∞
−∞
λ0(t)exp(β1D + β2X + γ1δ + ν)
× exp(−Λ0(t)exp(β1D + β2X + γ1δ + ν)
dF (ν|R,X)∫ ∞
−∞
S(t|D,R,X, ν)dF (ν|D,R,X) =
∫ ∞
−∞
exp(−Λ0(t)exp(β1D + β2X + γ1δ + ν)
dF (ν|R,X)
where cumulative hazard function Λ0(t) is defined as
Λ0(t) =
∫ ∞
−∞
λ0(u)du
Then, equation (D.3) becomes
λ(t|D, δ,X) = λ0(t)exp(β1D + β2X + γ1δ)g(t,D,R,X), (D.4)
where
g(t,D,R,X) =
∫∞
−∞ exp(ν)(exp(−Λ0(t)exp(β1D + β2X + γ1δ + ν)dF (ν|R,X)∫∞
−∞ exp(−Λ0(t)exp(β1D + β2X + γ1δ + ν)dF (ν|R,X)
(D.5)
In equation (D.4), when β3 − kcos(θ)a3 = 0, ν = 0 and g(t,D,R,X) = 1. When β1 = 0,
g(t,D,R,X) does not contain exposure D. Thus, β∗1 in model (D.2) and β1 in model (D.1) are
the same. Under these two conditions, the 2SRI Cox proportional hazard model estimates
the conditional causal parameter β1 consistently.
(2) Two stage predictor substitution: Under the 2SPS Cox proportional hazard model, the log
hazard function of T conditional on instrumental variable R, observed covariates X, and
unmeasured covariates U
log{λ(t|R,X),U} = β0(t) + β1E(D|R,X) + β2X + ε, (D.6)
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where
β0(t) = log(λ0(t)) unspecified baseline log hazard function
ε = (β1α3 + β3)U
When covariates U are not measured and ε is omitted, the conditional hazard function of T ,
conditional on {R,X}, is defined as
log{λ(t|R,X)} = β∗0(t) + β∗1E(D|R,X) + β∗2X (D.7)
where
β∗0(t) = log(λ
∗
0(t)) unspecified baseline log hazard function
As in previous section, the bias term g(t, R,X) for the 2SPS Cox proportional hazard model
can be derived as
λ(t|R,X) = λ0(t)exp(β1E(D|R,X) + β2X)g(t, R,X) (D.8)
where
g(t, R,X) =
∫∞
−∞ exp(ε)(exp(−Λ0(t)exp(β1E(D|R,X) + β2X + ε)dF (ε|R,X)∫∞
−∞ exp(−Λ0(t)exp(β1E(D|R,X) + β2X + ε)dF (ε|R,X)
(D.9)
where F (ε|R,X) is the conditional distribution function.
In equation (D.8), when β3α3+β3 = 0, ν = 0 and g(t, R,X) = 1. When β1 = 0, g(t, R,X) does
not contain exposure D. Thus, β∗1 in model (D.7) and β1 in model (D.6) are the same. Under
these two conditions, the 2SPS Cox proportional hazard model estimates the conditional
causal parameter β1 consistently.
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θ
‖β3‖cos(θ)a3 α3
β3 β3 − ‖β3‖cos(θ)a3
Figure 3.1: Decomposing β3 into two orthogonal components
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Figure 3.2: Boxplot of 2SRI Poisson model estimates when treatment effect is nonzero.
β1 is treatment effect; β3 is effect of unmeasured covariates on outcome. Bias is the
difference between estimates and true treatment effect
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Figure 3.3: Boxplot of 2SRI logistic model estimates when treatment effect is nonzero.
β1 is treatment effect; β3 is effect of unmeasured covariates on outcome. Bias is the
difference between estimates and true treatment effect.
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models
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CHAPTER 4
A CONDITIONAL LOG RANK TEST ADJUSTED WITH PROPENSITY SCORE TO
COMPARE SURVIVAL DISTRIBUTIONS
4.1. Introduction
Confounding is a major problem arising from non-randomized observational studies, in which an
extraneous variable may correlate with both treatment variable and outcome variable at the same
time. The confounding could bias the estimate of the treatment effect if it is not controlled for. A
common approach to correct for the biased estimate of the treatment effect resulting from con-
founding is to include both confounding variables and treatment variable in the same regression
model. When encountering right censored time to event data, clinical researchers routinely resort
to the multivariable Cox proportional hazard model.
The Cox proportional hazards model assumes that the relationship of the hazard rate at time t given
the covariates X and treatment indicator Z can be specified as the following log linear functional
form
λ(t|Z = z,X = x) = λ0(t)exp(βz + αTx) (4.1)
where λ0 is the unspecified baseline hazard, Z denotes binary treatment variable (Z=1 if subject
receives treatment, Z=0 if subject receives the placebo), X is a p-dimensional vector consisting of
measured confounding variables (X1, X2, ..., Xp)T at the baseline, β is the regression coefficient
associated with Z, α is a p-dimensional vector of regression coefficients for X. The underlying
proportional hazard assumption requires that for any two sets of variables (z1, x1) and (z0, x0), the
ratio of two hazard functions λ(t|Z=z1,X=x1)λ(t|Z=z0,X=x0) is time invariant.
we maximize the following partial likelihood to get the maximum partial likelihood estimator θ̂ =
(β̂, α̂),
L(β, α) =
n∏
i=1
[
exp(βzi + αTxi)∑
j∈Ri exp(βzi + α
Txi)
]δi (4.2)
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where Ri is the set of subjects at risk at time t and δi indicates a failure or not at time t.
The parameter of interest β measures the "treatment effect" of Z. Thus, we could test the null
hypothesis of no treatment effect H0 : β = 0 using the covariates adjusted Cox score test. When
the model (4.1) is correctly specified, the adjusted Cox score test is
[Uβ(0, α̂(0))]
T [Jββ(0, α̂(0))][Uβ(0, α̂(0))] ∼ χ2α,1
where α̂(0) is the restricted m.l.e of α given β = 0, and
Uβ(β, α) =
∂log(L(β, α))
∂β
,
Jββ(β, α) =
∂2log(L(β, α))
∂2α
/(
∂2log(L(β, α))
∂2β
∂2log(L(β, α))
∂2α
− (∂
2log(L(β, α))
∂β∂α
)2)
When the model (4.1) is misspecified, such as some variables are omitted from the model, Lin
and Wei, 1989 proposed a robust sandwich estimator for the variance of proportional hazard score
test statistics. With this robust variance estimator used, the score test is still valid under model
misspecification if the treatment variable Z is independent of covariates X.
Kong and Slud, 1997 extended Lin and Wei’s approach under a more general condition that the
treatment variable Z is independent of covariates X for subjects at risk at any given time t and a
more general functional forms of X.
Heller and Venkatraman, 2004 proposed a covariate adjusted non-parametric test for comparing
survival distributions among multiple groups. The validity of this non-parametric test does not re-
quire either proportional hazard assumption or any independence assumption between treatment
variable Z and covariates X. The use of kernel smoothing to estimate the expectation of treat-
ment indicator Z conditional on covariate X among subjects at risk at each time t requires that the
number of covariates could not exceed 3 due to the curse of dimensionality.
To extend Heller and Venkatraman’s conditional log rank test, we introduced the propensity score
to balance the unbalanced distribution of covariates X among treatment groups and reduce the
dimensionality of covariate X for kernel smoothing. In section 2, we discussed the extension of
conditional log rank test using propensity score. In section 3, simulation studies were performed
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to compare the size and power of log rank, adjusted Cox score test, Lin and Wei’s robust score
test, Kong and Slud’s robust score test, and the extended conditional log rank test under various
scenarios. Section 4 provides a data example. Section 5 discuss the findings.
4.2. Test Statistic
4.2.1. Notation and Assumption
For the ith subject, let Si denote the survival time and Ci represent censoring time. Ti = min(Si, Ci)
is the observed survival time. δi is censoring indicator, which is equal to 1 if Si ≤ Ci and 0 otherwise.
Ni(t) = I(Ti ≤ t, δi = 1) is the counting process that count the number of observed events (0 or
1) for the ith subject, and Yi(t) = I(Ti ≥ t) is the at-risk process, which indicates whether the ith
subject is at risk right before time t.
We make the following assumptions: i) let Xi denote the p-dimensional vector of confounding
variables (Xi1, Xi2, ..., Xip)T observed prior to treatment assignment for the ith subject, and there
is no other unmeasured confounding variables at baseline; ii) let e(X) denote a known propensity
score function. The distribution of covariates X conditional on e(X) between two treatment groups
(Z=1 vs. Z=0) are the same: X ⊥ Z|e(X). Let b(X) be a function of X and finer than e(X). iii)
the random vectors (Si, Ci, Zi, Xi), i = 1, 2, 3....n are independently and identically distributed. iv)
the failure time S and censoring time C are independent conditional on treatment variable Z and
covariates X.
4.2.2. Propensity score
4.2.3. Constructing the Test
The null hypothesis that the conditional hazard functions of two treatment groups given measured
covariates X are the same is:
λ0(t|x) = λ1(t|x) ∀t, x
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Following the steps listed by Heller and Venkatraman, 2004, we first have that
E(dN(t)|past) = P(dN(t) = 1|past)
= λ(t)dtI(T ≥ t)
= λ(t)Y (t)dt
Thus, under the independence assumption of the failure time and censoring time conditional on co-
variates (X,Z), Heller and Venkatraman, 2004 defined the relationship between counting process,
at risk process, and the covariates by
E(dN(t)|Y (t), X, Z) = Y (t)Zλ1(t|X)dt+ Y (t)(1− Z)λ0(t|X)dt (4.3)
where λj(t|x) represents the conditional hazard for a subject with group variable z = j. Based on
the expression (1), the counting process for the treatment group (Z = 1) can be defined by
E(ZdN(t)|Y (t), X) = Y (t)E(Z|Y (t), X)λ1(t|X)dt
Next,take the expectation of both sides (with respect to Z) under the null hypothesis that λ0(t|X) =
λ1(t|X) = λ(t|X), we have
EZ(E(ZdN(t)|Y (t), X, Z)) = EZ(Y (t)Zλ1(t|X)dt|Y (t), X)
= Y (t)λ(t|X)E(Z|Y (t), X)dt under H0 (4.4)
Since E(Z|Y (t), X) is a function of (Y (t), X), equation (2) shows that under H0 the counting
process is independent of group assignment. Heller and Venkatraman, 2004 constructed a non-
parametric test using empirical estimates the left- and right-hand s ides of equation (2) and specif-
ically, conditional expectation E(ZdN(t)|Y (t) = 1, X = xi) is constructed non-parametrically using
kernel smoothing function
E(Z|Y (t) = 1, X = xi) =
∑
j Yj(t)zjKg(xj , xi)∑
j Yj(t)Kg(xj , xi)
(4.5)
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when X is p dimensional covariate vector (p > 1), the multivariate kernel function Kg is defined as
Kg(u) =
p∏
l=1
g−1l k(g
−1
l ul)
where g is p dimensional vector of bandwidth controlling the degree of smoothness for each element
of covariate vector X.
However, the multivariate kernel smoothing suffers from the curse of dimensionality when p≥ 3.
That is, the number of neighboring data points around any value X in a higher dimensional space
will be very small, unless the sample size is extremely large (Hastie,2010).
Based on theorem (2) from Rosenbaum and Rubin, 1983, b(X) is a 1-dimensional balancing score
function of p-dimensional baseline covariates X such that
X ⊥ Z|b(X)
and,
E(Z|Y (t0) = 1, X = xi) = E(Z|Y (t0) = 1, X = bi(x))
where t0 is the baseline or the study beginning time point.
Under independence censoring assumption, the patients censored at time tc have the same risk as
the patients not censored at the same time. Thus, it can be inferred that there are no unmeasured
factors correlating with both Z and T during the study time period. It then follows
E(Z|Y (t) = 1, X = xi) = E(Z|Y (t) = 1, X = bi(x)) (4.6)
for each time point t. Because e(X) itself is the coarsest balancing score function, the equation
(2.4) remains valid with e(X) replacing b(X). Therefore, equation (2.3) can be re-expressed as
E(Z|Y (t) = 1, X = ei(x)) =
∑
j Yj(t)zjKg(ej(x), ei(x))∑
j Yj(t)Kg(ej(x), ei(x))
(4.7)
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Then from equation (2) and using the fact that
E(dN(t)|X) = λ(t|X)Y (t)dt
a conditional log rank test statistics Sn adjusting for balancing score function e(x) can be derived
as
Sn =
∑
i
∫
zidNi(t)−
∑
i
∫ ∑
j Yj(t)zjKg(ej(x), ei(x))∑
j Yj(t)Kg(ej(x), ei(x))
dNi(t) (4.8)
This statistics was able to be re-expressed as a function of difference in the estimated conditional
hazards between treatment and control groups (Heller and Venkatraman, 2004). It follows from
theorem 1 (Heller and Venkatraman, 2004) that under the null hypothesis that λ0(t|x) = λ1(t|x) =
λ(t|x),
n−1/2Sn → N(0, V )
where asymptotic variance V is estimated consistently by
∑
i
v̂ii
2 +
∑
i 6=j
v̂ij(2v̂ii + 2v̂jj + v̂ij + v̂ji) +
∑
i 6=j 6=l
v̂ij(v̂ij v̂il + v̂ij v̂li + v̂ij v̂jl + v̂ij v̂lj)
and
v̂ij = δi(zi −
α1(xi, ti)
α0(xi, xi)
− I(tj ≥ ti)Kb(xj , xi)
α0(xi, ti)
(zj −
α1(xi, ti)
α0(xi, ti)
))
and αj(x, t) = αj1(x, t) + αj0(x, t), j = 0, 1 The propensity score function e(X) for baseline covari-
ates X can be estimated consistently under correct model specification using logistic regression
model
e(x) = P (Z = 1|X) = e
βX
1 + eβX
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4.3. Simulation study
In this section, we performed a series of simulations to evaluate the type 1 error rate and the
statistical power for the log rank test, the covariates adjusted Cox score test, Lin and Wei robust
method, Kong and Slud robust method, and the propensity score adjusted conditional log rank test.
We considered the following factors in the simulation study design:
a. Proportional hazards assumption holds or not. The association between time to event T and
covariates (Z,X) can be expressed by a log linear model log(T |Z = z,X = x) = βz + αTx + ε.
When the error term ε ∼ standard extreme value distribution, the proportional hazard assumption
holds. When the error term ε ∼ N(0, σ2), the proportional hazard assumption will be violated.
b. The strength of association between confoundersX and treatment indicator Z. We used different
values of R2ps = (0.25,0.5,0.75) from propensity score model logit(Z|X = x) = lTx to specify the
low, medium, and high level of association between confounders X and treatment indicator Z. The
R2ps can be computed by tuning parameter γ as the following (Heller and Venkatraman, 2004):
R2ps = var(γl
Tx)/(var(γlTx) + π2)
c. The strength of association between confounders X and time to event T . Similarly, we also used
3 different values of R2cox = (0.25,0.5,0.75) to specify the low, medium, and high level of association
between confounders X and T . The R2cox can be computed by tuning parameter φ as the following
(Heller and Venkatraman, 2004):
R2cox = var(φα
Tx)/(var(φαTx) + var(ε))
d. Two different levels of censoring proportions (25%,50%) were specified.
e. Two different proportions of treated subjects (vs. subjects in placebo group): 30% and 50% were
specified. This can be done by tuning the intercept term in the propensity score model.
Thus, we have 72 different combination of scenarios. For each scenario, we generate the data in
the following steps:
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1. 10 confounders X were simulated. X1 ∼ N(10,2), X2 ∼ N(30,5), X3 ∼ 10 + 3 ∗ Uniform(0, 1),
X4 ∼ Bernoulli(p = 0.5) , X5 ∼ Pois(µ = 10), X6 ∼ log Normal(µ = 4.16, σ2 = 4.96), X7 ∼
exp(λ = 1.5), X8 ∼ 12 + Gamma(k = 9, r = 2), X9 ∼ 3 + 0.5Pois(µ = 10) + 1.5N(0, 1), and
X10 ∼ 12.5 + 0.8N(0, 1) + 2Uniform(0, 1);
2. The binary treatment indicator Zi for the ith subject is generated using Bernoulli(Pi(Zi|Xi)),
where Pi(Zi|Xi) is determined by covariates Xi through a logit function: logit(P (Zi = 1|Xi =
xi)) = l
T ∗xi. Xi is a 10-dimensional vector and lT is set to (l0,0.16,0.65,-0.58,1.68,-0.4,0.09,-0.2,-
0.69,0.28,0.74). When l0 is -10.5, we have ∼ 50% subjects receiving treatment. When l0 is -13.8,
we have ∼ 30% subjects receiving treatment.
3. The time to event Ti for the ith subject was generated from the log linear model log(Ti|Zi =
zi, Xi = Xi) = βzi + α
Txi + ε. β = 0 when we evaluate the type I error rate and β = 0.7(OR = 2)
when we evaluate the power. αT is set to (-0.2,0.013,-0.13,0.09,-0.07,0.06,0.22,0.19,0.11,-0.19).
The censoring time Ci is generated from uniform distribution (0,c). The values of c were determined
for the desired censoring proportion 25% and 50%.
We repeat the same process for 1500 times. In each replication, the sample size was set to 600.
The simulation results were presented in Figure 4.1 and 4.2. The results are mixed for type I error
rate and power. Figure 4.1 reveals that the propensity score adjusted log rank test outperform all
other methods and retain its nominal level in most simulation scenarios. However, propensity score
adjusted conditional log rank test only performs better than Kong and Slud’s robust score test in
terms of power.
4.4. Discussion
When clinical researchers compare the survival distributions between two treatment groups in a
observational study, a Cox proportional hazard model including the binary treatment indicator and
observed covariates is commonly used when proportional hazard assumption is reasonable. When
such assumption is not valid, Lin and Wei, 1989 and Kong and Slud, 1997 have proposed covari-
ates adjusted robust score statistics but under the assumption that the treatment group indicator is
independent of all other covariates, which makes their tests not suitable for observational studies
because independence occurs mainly in randomized studies. Heller and Venkatraman, 2004 pro-
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posed a non-parametric conditional log rank test for right censored survival data, which does not
require the proportional hazard assumption and the independence assumption between treatment
group variable and all other covariates. Although this method is desirable for comparing treatment
effect in observation studies, the authors used kernel smoothing to estimate the expectation of treat-
ment variable conditional on covariates among the subjects at risk and in such way, covariates are
incorporated into the test statistics. Due to the curse of dimensionality on non-parametric smooth-
ing methods such as kernel smoothing. There is a limitation on the number of covariates that can
be controlled for and no more than three variables) are allowed for a satisfactory performance.
In this paper, we proposed a simple extension to the conditional log rank test by using propensity
score as a summary score of all the confounders. In this way, we reduce the dimension of the
covariates and apply the kernel smoothing on the scalar propensity score. Thus, limitation imposed
on conditional log rank is removed. The propensity score adjusted conditional log rank could be an
robust alternative to confounders adjusted Cox proportional hazard models when the proportional
hazard assumption does not hold.
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CHAPTER 5
DISCUSSION
This dissertation made several contributions to the causal inference, particularly two stage IV meth-
ods. In chapter 2 we investigated the consistency of 2SPS and 2SRI methods in estimating the
causal hazard ratio among compilers. Under principal stratification and potential outcome frame-
work, we assume the potential survival time in each compliance group (e.g. always taker, never
taker, complier) follows Weibull distribution with the same shape parameter but different scale pa-
rameters for receiving active treatment or control. For 2SPS, the true local treatment effect is the
log causal hazard hazard among complier, which is defined as difference in log scale parameters
when treated and not treated among compliers, weighted by negative shape parameter. we first
showed that the second stage Weibull model including predicted treatment status is equivalent to
the Weibull model including binary treatment assignment status (IV) because predicted treatment
received status has a one-to-one relationship with IV. This re-parameterization does not change
values of linear predictor of a Weibull model. Next, we showed that the 2SPS estimator is equal
to the difference between log hazard among subjects assigned to treatment (R=1) and log hazard
among subjects assigned to control (R=0), divided by proportion of the complier in the study pop-
ulation. Subjects assigned to either active treatment or control groups are heterogeneous and are
mixture of always takers, never takers, and compliers. The distribution of these subjects’ survival
times does not follow Weibull distribution any more. However, Weibull model assumes these het-
erogeneous subjects assigned to each arm homogeneous and impose a Weibull distribution upon
them. The distributional parameters are chosen in such way that makes this Weibull distribution as
close to the true mixture distribution as possible. Thus, 2SPS estimator can not be simplified into
an expression consisting of distributional parameters from the complier only. Utilizing this fact, we
derived the closed form expression of the probability limit of 2SPS estimator in terms of defined
parameters of potential survival times for always taker, never taker, and complier. The difference
between this expression of probability limit of 2SPS estimator and the true log causal hazard ratio
is the asymptotic bias of 2SPS estimator. To derive the close form expression of asymptotic bias
of 2SRI estimator, we can only derive the closed form expression of the asymptotic bias under the
assumption that there is no always taker, although we can still evaluate the consistency of 2SRI
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estimator without imposing no always taker assumption using simulation. The true model should
include an interaction term between the treatment received and the residual term, thus 2SRI is
a mis-specified model. Similarly, the second stage 2SRI Weibull model including treatment re-
ceived indicator and residual term is equivalent to a model including treatment received indicator
and treatment assignment indicator (IV). Such re-parameterization does not change the values of
linear predictors of Weibull model. Utilizing this relationship between two Weibull models, we de-
rived the closed form expression of asymptotic bias of 2SRI estimator. Through analytic formula
and simulations, we showed that when we use two stage IV methods to estimate the causal haz-
ard ratio among compliers, 2SPS estimator is less volatile and perform better than 2SRI estimator
when the hazard is a decreasing function (α < 1) but both 2SRI and 2SPS estimators have very
large variability when the hazard is an increasing function (α > 1). Another interesting finding is
that the biases of 2SPS and 2SRI estimators are also associated with censoring distribution. The
closed form expression of asymptotic bias for 2SPS and 2SRI are useful when we design a two
arm trial with possible non-compliance to determine the magnitude of bias of using the two stage
IV method in estimating the causal hazard ratio among compliers. In chapter 3, we studied the
consistency of two stage IV methods from another perspective. that is, Are 2SPS and 2SRi bi-
ased in estimating conditional treatment effect given observed and unobserved covariates? The
current two stage modeling framework are very restrictive and may not be suitable for clinical set-
tings involving a single endogenous exposure variable and multiple unmeasured covariates. Under
this new framework, we successfully demonstrated the consistency problems of 2SPS and 2SRI
in estimating the conditional treatment effect in non-linear model context can be transformed into
the omitted-variable bias problems in non-linear models. The latter question is a topic under ex-
tensive research. Using this result, we easily revealed that 2SPS and 2SRI are unbiased under
the null hypothesis that there is no causal effect for Poisson, logistic, and Cox proportional hazard
models. When the treatment effect is not null, the results are mixed. 2SPS and 2SRI are unbi-
ased for Poisson model but the two methods are biased for logistic and Cox proportional hazard
model. The biases are influenced by several factors: (1) larger magnitude of treatment effect is
associated with larger biases; (2) larger magnitude of the effects of unobserved covariates is as-
sociated with larger biases; (3) The magnitude of coefficients of omitted error terms in 2SPS and
2SRI are associated with the biases. Specially for 2SRI, the coefficient of omitted error term can
be represented by a dissimilarity metric sin(θ). This sine dissimilarity metric measures the dis-
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tance between two coefficient vectors of unmeasured covariates in both treatment and outcome
models. As two coefficient vectors are more dissimilar, the bias becomes larger. (4) For time to
event outcome, we found via simulation that 2 stage IV methods have smaller biases when the
hazard is a decreasing function (α < 1), and larger biases when the hazard is a increasing function
(α > 1). This finding is consistent with our results in chapter 2. Overall, 2SRI performs better than
2SPS when estimating the conditional treatment effect. This new two stage modeling framework
and related techniques presented in chapter 3 have several immediate extensions. For example,
we can use this new framework to assess the bias in estimating the conditional treatment effect
when using propensity score adjusted non-linear regression models, rather than using covariates
adjusted models. In chapter 4, we discussed the extension of a covariates adjusted non-parametric
conditional log rank test by using propensity score as a summary score of measured covariates for
observational studies. This extension relaxed the limitation of Heller and Venkatraman’s conditional
log rank test (Heller and Venkatraman, 2004) on the number of covariates that can be adjusted.
Simulation shows that the propensity score adjusted conditional log rank test is satisfactory.
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